蜈蚣不同部分提取液对肝癌细胞Bel-7404移植瘤的抑制作用及毒理学研究
|
摘要
本课题前期研究表明全虫蜈蚣提取液(Extract of centipedes, ECP)对肝细胞肝癌(HCC)有一定的治疗作用,并对其治疗肝细胞肝癌的机制作了初步的探讨。我们在此基础上,进一步探讨蜈蚣头足部分、全虫部分、躯干部分提取液对实验性肝癌的抑制作用,并对蜈蚣不同部分提取液(Extract from different parts of Centipedes, ECPs)进行系统的毒理研究,通过观察ECPs的毒理学反应,以期确定ECPs的毒性大小、毒性作用的靶器官,以及探讨ECPs对肝脏毒性作用的机制,为临床合理选择用药提供实验基础。
第一章蜈蚣不同部分提取液对肝癌细胞Bel-7404移植瘤的抑制作用
目的：研究ECPs在体内对肝癌细胞Bel-7404移植瘤的抑制作用。
方法：建立裸鼠Bel-7404人异位肝癌移植模型,以ECPs予以灌服,观察肿瘤生长及肝癌转移情况。
结果：①裸鼠Bel-7404人异位肝癌移植模型成功率100%；②ECPs对裸鼠Bel-7404移植瘤有明显抑制作用,移植瘤术后30天,荷瘤对照组肿瘤体积为1000.5+87.4mm3,而头足组、全虫组、躯干组肿瘤体积分别为：460.3+61.7、526.1±75.7、530.7±81.3mm3。移植瘤重量荷瘤对照组为1120.01±101.94mg,而头足组、全虫组、躯干组肿瘤分别为593.73±37.01、659.57+62.88、669.42±45.00mg,对照组与治疗组间均有明显统计学差异(P<0.05),计算头足组、全虫组、躯干组肿瘤抑制率分别达到46.99%、41.11%、40.23%。头足组、全虫组、躯干组组间比较,全虫组与躯干组平均肿瘤重量较为接近,无显著性差异；而头足组平均肿瘤重量低于全虫组与躯干组,有显著性差异(P<0.05)。
结论：①成功建立人肝癌Bel-7404细胞株裸鼠移植瘤动物模型；②ECPs以10g生药/kg的剂量给药时,有抑制裸鼠Bel-7404移植瘤的作用,其中头足提取液抑瘤作用更显著。
第二章蜈蚣不同部分提取液的毒性研究
目的：通过急性毒性试验和长期毒性试验评价ECPs的一般毒性作用；通过体内微核试验、精子畸形试验、Ames试验评价ECPs的遗传毒性作用。
方法：
(1)急性毒性试验：用不同剂量ECPs灌胃昆明小鼠,观察小鼠活动、毒性反应及死亡情况。
(2)长期毒性试验：用不同剂量ECPs灌胃SD大鼠,观察动物的反应及体重变化,分别于第4周和第13周取血作血常规及生化检查及行病理解剖,检查主要脏器的病理变化及计算脏器系数。留下的动物停药后继续观察2周(第15周)后再活杀,了解毒性反应的恢复情况和可能出现的延迟性毒性。
(3)遗传毒性试验：①微核试验：用不同剂量ECPs灌胃昆明小鼠。给药后取股骨骨髓细胞制作涂片,观察含有微核的嗜多染红细胞数,以微核率表示。②精子畸变试验：用不同剂量ECPs灌胃昆明小鼠。给药后附睾滤液制作涂片,观察畸形精子数,计算其畸变率。③AMES试验：采用标准平板法,计数每皿上长出的回变菌落数。
结果：
(1)急性毒性试验：头足组的LD5o为39.18g生药/kg,95%平均可信区间32.89-45.01g生药/kg；全虫组的LD5o为51.20g生药/kg,95%平均可信区间41.81-59.97g生药/kg,躯干组LD5o为53.85g生药/kg,95%平均可信区间45.09-62.12g生药/kg。
(2)长期毒性试验：①一般生理指标：实验初期ECPs可引起部分动物呕吐和大便性状改变,随后可缓解。实验过程中,与同期对照组相比,ECPs对SD大鼠摄食量无明显影响；ECPs可引起头足高剂量组大鼠体重增长减慢。②血液学指标：给药期间(第4周,第13周),与同期对照组相比,ECPs可引起RBC、HB降低,ALT、AST增高,BUN、CREA增高,PT、TT、APTT延长,并且有显著性差异(P<0.01,P<0.05)；到恢复期结束,除头足高剂量组ALT、AST外,其它指标基本恢复正常。同时期同处理组不同剂量水平组内比较：高、低剂量之间,以上指标存在统计学差异。同时期同剂量水平不同处理组组间比较：低剂量时,各组间以上指标无统计学差异；高剂量时,头足组与全虫组、头足组与躯干组比较,ALT、AST、BUN、CREA、PT、 APTT存在统计学差异(P<0.01,P<0.05),而全虫组与躯干组比较,无显著性差异(P>0.05)。③病理检查：处死大鼠行病理学检查,各组对脏器系数无明显影响。给药期间,头足中高剂量组、全虫高剂量组、躯干高剂量组可引起肝细胞肿胀改变,头足高剂量组甚至导致肝脏坏死改变,还可引起肾脏轻度水变性改变。停药后2周,肝肾损害程度减轻,肾脏基本恢复正常,部分肝脏遗留坏死改变。各组对心脏、脑、肺脏、脾脏组织无明显损害。
(3)遗传毒性试验：①微核试验：蜈蚣提取液各剂量组微核率与阴性对照组之间无显著性差异(P>0.05),而环磷酰胺阳性对照组与阴性对照组间有显著性差异(P<0.01),说明该蜈蚣提取液无致小鼠骨髓嗜多染红细胞微核增生作用。②精子畸形试验：蜈蚣提取液对大鼠精子畸形发生率无明显影响,各剂量组与阴性对照组比较差异无显著性(P>0.05),而阳性对照组与阴性对照组有显著性差异(P<0.01),说明蜈蚣提取液无致小鼠精子畸形作用。③Ames试验：阳性对照组的回变菌落数超过白发回变对照组菌落数的2倍,而蜈蚣提取液各剂量组的回变菌落数均末超过自发回变菌对照组落数的2倍,结果为阴性。
结论：①中药蜈蚣头足部分提取液为小毒,全虫部分、躯干部分提取液毒性接近,毒性更小。②相同剂量下,中药蜈蚣不同提取液的毒性大小依次为：头足部分>全虫部分三躯干部分。③ECPs可引起肝肾损害和凝血功能异常,肝脏、肾脏、血液系统可能为主要的毒性靶器官,其中肝脏损害较重,而肾脏和血液系统损害相对较轻。④ECPs在本实验条件下无明显遗传毒性作用。⑤临床治疗肝癌时,以蜈蚣全虫入药为宜,并且可适当加大蜈蚣的用量。
第三章蜈蚣不同部分提取液对肝脏毒性损害机制研究
目的：通过检测SD大鼠肝脏组织MDA、SOD、CytP450、TNF-α、IL-6水平,探讨ECPs对肝脏毒性损害的机制。
方法：硫代巴比妥酸法检测肝组织MDA含量,黄嘌呤氧化酶法检测肝组织SOD活力,CO还原差示光谱法(Omura法)测定肝组织CytP450含量,双抗体夹心ABC-酶联免疫吸附试验(ELISA)检测肝组织TNF-a、IL-6。
结果：与同期对照组相比,ECPs可引起MDA水平增高、SOD活力降低、CytP450含量降低、TNF-α、IL-6含量增高,差异显著(P<0.01,P<0.05)；其中头足高剂量组IL-6、TNF-α的差异到恢复期结束仍然存在(P<0.05)。同时期同处理组不同剂量水平组内比较：高、低剂量之间,以上指标存在统计学差异。同时期同剂量水平不同处理组组间比较：低剂量时,各组间以上指标无统计学差异；高剂量时,头足组与全虫组、头足组与躯干组比较,MDA、SOD、CytP450、TNF-α、IL-6存在统计学差异(P<0.01,P<0.05),而全虫组与躯干组比较,无显著性差异(P>0.05)。
结论：①ECPs可引起肝组织MDA水平增高、SOD活力下降,通过脂质过氧化导致肝细胞化学性损伤。②ECPs可引起肝组织TNF、IL-6水平增高,通过诱导细胞因子、炎性因子等对肝细胞产生免疫性损伤。③ECPs可引起肝组织CytP450水平下降,提示中药蜈蚣可能通过影响动物体内组胺—HP450这一途径对肝脏造成损伤。
The previous research of this programme initially clarified that the extract of Centipedes(ECP) has some therapeutic effect on Hepatocellular carcinoma(HCC), and made an initial probe into the mechanism of ECP for the treatment of hepatocellular carcinoma. On the basis of the previous research, we plan to further approach inhibitive effect of extract from different parts of Centipedes(ECPs) on Bel-7404hepatic carcinoma xenografts and make a systematic toxicological study on ECPs-through observing the different toxicological reactions caused by ECPs try to determine the latter's toxicity and the target organs of the toxicity, and to probe into the mechanism of the toxicity on the target organs, so that an experimental basis can be provided for reasonable choice of clinical medication.
Chapter One:Inhibitive Effect of ECPs on Bel-7404hepatic carcinoma xenografts
Objective:To investigate the inhibitive effect of ECPs on Bel-7404hepatic carcinoma xenografts.
Method:To set up model of Bel-7404hepatic carcinoma xenografts in nude mouse,and observe its tumor growth and metastasis by intragastric administration of ECPs.
Result:①The achievement ratio for Bel-7404hepatic carcinoma xenografts in nude mouse is100%.②ECPs had distinctive inhibitive effect on Bel-7404hepatic carcinoma xenografts in nude mouse. At the30st day postgraft of nude mouse,the average cancer volume of the contrast group was1000.5±87.4mm3, and that of the treatment groups are460.3±61.7、526.1±75.7、530.7±81.3mmj respectively; the average grafting carcinoma weight of the contrast group was1120.01±101.94mg, but that of the treatment groups were593.73±37.01、659.57±62.88、669.42±45.00mg respectively; all these differences are all distinctive (P<0.05). The inhibitive ratio of the head&foot group, the holo-centipede group and the truck group reach46.990%、41.11%、40.23%respectively. The average weight of the grafting carcinoma in the holo-centipede group and the truck group are of no significant difference; but that of the head&foot gorup is less than the other two groups, the difference is significant (P<0.05).
Conclusion:①The model of Bel-7404hepatic carcinoma xenografts in nude mouse is set up successfully;②ECPs(10g/kg) can inhibit Bel-7404hepatic carcinoma xenografts in nude mouse; Extract from the head&foot of centipede has the most significant inhibitive effect.
Chapter Two:Toxicity study on extract from different parts of centipedes
Objective:To evaluate the general toxicity of the ECPs through acute toxicity test and long-term toxicity test. To evaluate the genetic toxicity of the ECPs through Micronucleus test, Sperm Malformation Test and Ames Test.
Method:(1)Acute toxicity test:The KM mice were lavaged with the different dose of ECPs, and their activities, reactions and death were observed.(2)Long-term toxicity test:The SD rats were lavaged with the different dose of ECPs in successive4weeks and13weeks, and their reactions and weight changes were observed. The blood routine test and biochemical test were detected. Then pathological anatomy was done on the rats, and the organ coefficient was calculated.(3)Genetic toxicity test:①Micronucleus test:The different dose of ECPs were lavaged to the rats, Then1000polychromatic erythrocytes (PCE) per rat were counted on each smear and get the micronucleus rates.②Sperm Malformation Test: The different dose of ECPs were the same to the micronucleus test.1000sperm cells per rat were observed through the light microscope and the aberration rate was got.③Ames test:Standard plate method was used. The numbers of the strains in each culture dish were scored.
Result:
(1)Acute toxicity test:Through the acute toxicity test, the LD50of the head&food group was39.18g/kg, with the average95%confidence interval (CI)32.89～45.01g/kg; the LD50of the holo-centipede group was51.20g/kg, with the average95%CI41.81～59.97g/kg; and the LD50of the trunk group was53.85g/kg, with the average95%CI45.09～62.12g/kg.
(2)Long-term toxicity test:①General physiological indices:Early in the experiment, ECPs caused some animals vomit and changes of stool trait, then the symptom could be relieved. Compared with the contrast group of the same period, no influence on the SD rats'food intake was found in any group during the experiment.But the group of rats lavaged with high dose of extract from the head&food of centipede were found conspicuous hold-back in their weight growth.②Hematological indices: During the period of administration (in the4th and the13th week), compared with the contrast group of the same period, it was found that, ECPs caused a drop in RBC and Hb, a raise in ALT, AST, BUN, and CREA, and extended PT、TT、APTT, and was found significant difference (P<0.01, P<0.05). When the convalescence is over (in the15th week), all the other indicators mentioned above, except ALT and AST, basically recovered to their normal level. Comparison among the groups of the same period with the same treatment but different dose level:significant differences were found between the high dose group and the low dose group.Comparison among the groups of the same period with the same dose level but different treatment:In the level of low dose, no differences was found having statistical sense; In the level of high dose, Significant differences were found in ALT、AST、BUN、CREA、PT、APTT between the head&foot group and the holo-centipede group, and between the head&foot group and the trunk group(P<0.01, P<0.05);but no difference was found between the holo-centipede group and the trunk group(P>0.05).③Pathological examination:After the experiment, the rats were killed and pathological examination was made on them. The results show that the groups of any dose level have no significant influence on organ coefficient. During the administration, high dose of head&foot extract, holo-centipede extract, and trunk extract caused swelling in the liver cells, especially the high dose of head&foot extract even caused liver necrosis, and mild cellular edema in kidney. When the convalescence was over, the damage on liver and kidney was reduced, the kidney basically recovered, hepatic necrosis remained. None group made significant damage on the rats' heart, brain, lung or spleen.
(3)Genetic toxicity test:①Micronucleus test:No significant deviation was found in micronucleus rate between all the groups lavaged with ECPs and their negative contrast groups (P>0.05); while high significant deviation was found between cyclophosphamide positive contrast group and negative contrast group (P<0.01). This shows that the ECPs have no effect on proliferation of mice polychromatic erythrocytes.②Sperm Malformation Test:No manifest effect by the ECPs was found on the sperm malformation of the mice; no significant deviation was found in any group (at different dose level) compared with their negative contrast group (P>0.05); and significant deviation was found in the positive control group compared with the negative contrast group (P<0.01). This shows that the ECPs have no effect on sperm malformation.③Ames test: The number of colony with back mutation in the positive contrast group exceeded the twice number of that in the negative contrast group; the number of colony with back mutation in varied strains of Salmonella typhimurium at different doses did not exceed the twice number of those with spontaneous mutation. The result of the test was negative.
Conclusion:①Extract from head&foot of centipedes had low toxicity, while the toxicity of extract from holo-centipede is similar to that of the trunk.②When at the same dose level, toxicity of ECPs is:head&foot extract>holo-centipede extract>trunk extract.③ECPs can cause dysfunction in liver, kidney, and coagulopathy; the main target organs may be liver, kidney, etc., while more damage will be caused on liver, and less on kidney and hematological system.④No genetic toxicity of ECPs was found under our experiment condition.⑤It is advisable to use holo-centipede, and to increase the dose appropriately in the clinical treatment of HCC.
Chapter Three:Experimental study on mechanisms of hepatotoxical damage in rats caused by ECPs
Objective:To probe into the toxicological mechanism of ECPs on liver damage through detecting the level of MDA, SOD, CytP450, TNF-α, and IL-6in the livers of SD rats.
Method:The MDA contents in livers were measured by the method of thiobarbituric acid reaction (TBA); the SOD activity of the livers was measured by Xanthine oxidase; the CytP450contents in livers were measured by Omura; TNF-a and IL-6in livers were measured by ELISA.
Result:Compared with the contrast group of the same period, it was found that, during the period of administration, ECPs caused a drop in SOD and CytP450, a raise in MDA, IL-6, TNF-α (P<0.01, P<0.05).When the convalescence is over, all the other indicators mentioned above, except IL-6and TNF-α, basically recovered to their normal level. Comparison among the groups of the same period with the same treatment but different dose level:significant differences were found between the high dose group and the low dose group.Comparison among the groups of the same period with the same dose level but different treatment:Significant differences in MDA. SOD. CytP450、TNF-α、IL-6were found between the head&foot group and the holo-centipede group, and between the head&foot group and the trunk group(P<0.01, P<0.05),but no significant difference was found between the holo-centipede group and the trunk group (P>0.05).
Conclusion:①ECPs can cause a raise in MDA contents and a drop in SOD activity, and may cause a chemical injury in liver cells through lipid peroxidation.②ECPs can cause a raise in TNF、IL-6contents and immunological injury in liver cells through inducing cytokine and inflammatory factors (such as TNF, IL-6,etc.).③ECPs can cause a drop in CytP450contents in liver, and the damage may be caused through affecting Histamine-HP450in the animals'body.
第一章蜈蚣不同部分提取液对肝癌细胞Bel-7404移植瘤的抑制作用
目的：研究ECPs在体内对肝癌细胞Bel-7404移植瘤的抑制作用。
方法：建立裸鼠Bel-7404人异位肝癌移植模型,以ECPs予以灌服,观察肿瘤生长及肝癌转移情况。
结果：①裸鼠Bel-7404人异位肝癌移植模型成功率100%；②ECPs对裸鼠Bel-7404移植瘤有明显抑制作用,移植瘤术后30天,荷瘤对照组肿瘤体积为1000.5+87.4mm3,而头足组、全虫组、躯干组肿瘤体积分别为：460.3+61.7、526.1±75.7、530.7±81.3mm3。移植瘤重量荷瘤对照组为1120.01±101.94mg,而头足组、全虫组、躯干组肿瘤分别为593.73±37.01、659.57+62.88、669.42±45.00mg,对照组与治疗组间均有明显统计学差异(P<0.05),计算头足组、全虫组、躯干组肿瘤抑制率分别达到46.99%、41.11%、40.23%。头足组、全虫组、躯干组组间比较,全虫组与躯干组平均肿瘤重量较为接近,无显著性差异；而头足组平均肿瘤重量低于全虫组与躯干组,有显著性差异(P<0.05)。
结论：①成功建立人肝癌Bel-7404细胞株裸鼠移植瘤动物模型；②ECPs以10g生药/kg的剂量给药时,有抑制裸鼠Bel-7404移植瘤的作用,其中头足提取液抑瘤作用更显著。
第二章蜈蚣不同部分提取液的毒性研究
目的：通过急性毒性试验和长期毒性试验评价ECPs的一般毒性作用；通过体内微核试验、精子畸形试验、Ames试验评价ECPs的遗传毒性作用。
方法：
(1)急性毒性试验：用不同剂量ECPs灌胃昆明小鼠,观察小鼠活动、毒性反应及死亡情况。
(2)长期毒性试验：用不同剂量ECPs灌胃SD大鼠,观察动物的反应及体重变化,分别于第4周和第13周取血作血常规及生化检查及行病理解剖,检查主要脏器的病理变化及计算脏器系数。留下的动物停药后继续观察2周(第15周)后再活杀,了解毒性反应的恢复情况和可能出现的延迟性毒性。
(3)遗传毒性试验：①微核试验：用不同剂量ECPs灌胃昆明小鼠。给药后取股骨骨髓细胞制作涂片,观察含有微核的嗜多染红细胞数,以微核率表示。②精子畸变试验：用不同剂量ECPs灌胃昆明小鼠。给药后附睾滤液制作涂片,观察畸形精子数,计算其畸变率。③AMES试验：采用标准平板法,计数每皿上长出的回变菌落数。
结果：
(1)急性毒性试验：头足组的LD5o为39.18g生药/kg,95%平均可信区间32.89-45.01g生药/kg；全虫组的LD5o为51.20g生药/kg,95%平均可信区间41.81-59.97g生药/kg,躯干组LD5o为53.85g生药/kg,95%平均可信区间45.09-62.12g生药/kg。
(2)长期毒性试验：①一般生理指标：实验初期ECPs可引起部分动物呕吐和大便性状改变,随后可缓解。实验过程中,与同期对照组相比,ECPs对SD大鼠摄食量无明显影响；ECPs可引起头足高剂量组大鼠体重增长减慢。②血液学指标：给药期间(第4周,第13周),与同期对照组相比,ECPs可引起RBC、HB降低,ALT、AST增高,BUN、CREA增高,PT、TT、APTT延长,并且有显著性差异(P<0.01,P<0.05)；到恢复期结束,除头足高剂量组ALT、AST外,其它指标基本恢复正常。同时期同处理组不同剂量水平组内比较：高、低剂量之间,以上指标存在统计学差异。同时期同剂量水平不同处理组组间比较：低剂量时,各组间以上指标无统计学差异；高剂量时,头足组与全虫组、头足组与躯干组比较,ALT、AST、BUN、CREA、PT、 APTT存在统计学差异(P<0.01,P<0.05),而全虫组与躯干组比较,无显著性差异(P>0.05)。③病理检查：处死大鼠行病理学检查,各组对脏器系数无明显影响。给药期间,头足中高剂量组、全虫高剂量组、躯干高剂量组可引起肝细胞肿胀改变,头足高剂量组甚至导致肝脏坏死改变,还可引起肾脏轻度水变性改变。停药后2周,肝肾损害程度减轻,肾脏基本恢复正常,部分肝脏遗留坏死改变。各组对心脏、脑、肺脏、脾脏组织无明显损害。
(3)遗传毒性试验：①微核试验：蜈蚣提取液各剂量组微核率与阴性对照组之间无显著性差异(P>0.05),而环磷酰胺阳性对照组与阴性对照组间有显著性差异(P<0.01),说明该蜈蚣提取液无致小鼠骨髓嗜多染红细胞微核增生作用。②精子畸形试验：蜈蚣提取液对大鼠精子畸形发生率无明显影响,各剂量组与阴性对照组比较差异无显著性(P>0.05),而阳性对照组与阴性对照组有显著性差异(P<0.01),说明蜈蚣提取液无致小鼠精子畸形作用。③Ames试验：阳性对照组的回变菌落数超过白发回变对照组菌落数的2倍,而蜈蚣提取液各剂量组的回变菌落数均末超过自发回变菌对照组落数的2倍,结果为阴性。
结论：①中药蜈蚣头足部分提取液为小毒,全虫部分、躯干部分提取液毒性接近,毒性更小。②相同剂量下,中药蜈蚣不同提取液的毒性大小依次为：头足部分>全虫部分三躯干部分。③ECPs可引起肝肾损害和凝血功能异常,肝脏、肾脏、血液系统可能为主要的毒性靶器官,其中肝脏损害较重,而肾脏和血液系统损害相对较轻。④ECPs在本实验条件下无明显遗传毒性作用。⑤临床治疗肝癌时,以蜈蚣全虫入药为宜,并且可适当加大蜈蚣的用量。
第三章蜈蚣不同部分提取液对肝脏毒性损害机制研究
目的：通过检测SD大鼠肝脏组织MDA、SOD、CytP450、TNF-α、IL-6水平,探讨ECPs对肝脏毒性损害的机制。
方法：硫代巴比妥酸法检测肝组织MDA含量,黄嘌呤氧化酶法检测肝组织SOD活力,CO还原差示光谱法(Omura法)测定肝组织CytP450含量,双抗体夹心ABC-酶联免疫吸附试验(ELISA)检测肝组织TNF-a、IL-6。
结果：与同期对照组相比,ECPs可引起MDA水平增高、SOD活力降低、CytP450含量降低、TNF-α、IL-6含量增高,差异显著(P<0.01,P<0.05)；其中头足高剂量组IL-6、TNF-α的差异到恢复期结束仍然存在(P<0.05)。同时期同处理组不同剂量水平组内比较：高、低剂量之间,以上指标存在统计学差异。同时期同剂量水平不同处理组组间比较：低剂量时,各组间以上指标无统计学差异；高剂量时,头足组与全虫组、头足组与躯干组比较,MDA、SOD、CytP450、TNF-α、IL-6存在统计学差异(P<0.01,P<0.05),而全虫组与躯干组比较,无显著性差异(P>0.05)。
结论：①ECPs可引起肝组织MDA水平增高、SOD活力下降,通过脂质过氧化导致肝细胞化学性损伤。②ECPs可引起肝组织TNF、IL-6水平增高,通过诱导细胞因子、炎性因子等对肝细胞产生免疫性损伤。③ECPs可引起肝组织CytP450水平下降,提示中药蜈蚣可能通过影响动物体内组胺—HP450这一途径对肝脏造成损伤。
The previous research of this programme initially clarified that the extract of Centipedes(ECP) has some therapeutic effect on Hepatocellular carcinoma(HCC), and made an initial probe into the mechanism of ECP for the treatment of hepatocellular carcinoma. On the basis of the previous research, we plan to further approach inhibitive effect of extract from different parts of Centipedes(ECPs) on Bel-7404hepatic carcinoma xenografts and make a systematic toxicological study on ECPs-through observing the different toxicological reactions caused by ECPs try to determine the latter's toxicity and the target organs of the toxicity, and to probe into the mechanism of the toxicity on the target organs, so that an experimental basis can be provided for reasonable choice of clinical medication.
Chapter One:Inhibitive Effect of ECPs on Bel-7404hepatic carcinoma xenografts
Objective:To investigate the inhibitive effect of ECPs on Bel-7404hepatic carcinoma xenografts.
Method:To set up model of Bel-7404hepatic carcinoma xenografts in nude mouse,and observe its tumor growth and metastasis by intragastric administration of ECPs.
Result:①The achievement ratio for Bel-7404hepatic carcinoma xenografts in nude mouse is100%.②ECPs had distinctive inhibitive effect on Bel-7404hepatic carcinoma xenografts in nude mouse. At the30st day postgraft of nude mouse,the average cancer volume of the contrast group was1000.5±87.4mm3, and that of the treatment groups are460.3±61.7、526.1±75.7、530.7±81.3mmj respectively; the average grafting carcinoma weight of the contrast group was1120.01±101.94mg, but that of the treatment groups were593.73±37.01、659.57±62.88、669.42±45.00mg respectively; all these differences are all distinctive (P<0.05). The inhibitive ratio of the head&foot group, the holo-centipede group and the truck group reach46.990%、41.11%、40.23%respectively. The average weight of the grafting carcinoma in the holo-centipede group and the truck group are of no significant difference; but that of the head&foot gorup is less than the other two groups, the difference is significant (P<0.05).
Conclusion:①The model of Bel-7404hepatic carcinoma xenografts in nude mouse is set up successfully;②ECPs(10g/kg) can inhibit Bel-7404hepatic carcinoma xenografts in nude mouse; Extract from the head&foot of centipede has the most significant inhibitive effect.
Chapter Two:Toxicity study on extract from different parts of centipedes
Objective:To evaluate the general toxicity of the ECPs through acute toxicity test and long-term toxicity test. To evaluate the genetic toxicity of the ECPs through Micronucleus test, Sperm Malformation Test and Ames Test.
Method:(1)Acute toxicity test:The KM mice were lavaged with the different dose of ECPs, and their activities, reactions and death were observed.(2)Long-term toxicity test:The SD rats were lavaged with the different dose of ECPs in successive4weeks and13weeks, and their reactions and weight changes were observed. The blood routine test and biochemical test were detected. Then pathological anatomy was done on the rats, and the organ coefficient was calculated.(3)Genetic toxicity test:①Micronucleus test:The different dose of ECPs were lavaged to the rats, Then1000polychromatic erythrocytes (PCE) per rat were counted on each smear and get the micronucleus rates.②Sperm Malformation Test: The different dose of ECPs were the same to the micronucleus test.1000sperm cells per rat were observed through the light microscope and the aberration rate was got.③Ames test:Standard plate method was used. The numbers of the strains in each culture dish were scored.
Result:
(1)Acute toxicity test:Through the acute toxicity test, the LD50of the head&food group was39.18g/kg, with the average95%confidence interval (CI)32.89～45.01g/kg; the LD50of the holo-centipede group was51.20g/kg, with the average95%CI41.81～59.97g/kg; and the LD50of the trunk group was53.85g/kg, with the average95%CI45.09～62.12g/kg.
(2)Long-term toxicity test:①General physiological indices:Early in the experiment, ECPs caused some animals vomit and changes of stool trait, then the symptom could be relieved. Compared with the contrast group of the same period, no influence on the SD rats'food intake was found in any group during the experiment.But the group of rats lavaged with high dose of extract from the head&food of centipede were found conspicuous hold-back in their weight growth.②Hematological indices: During the period of administration (in the4th and the13th week), compared with the contrast group of the same period, it was found that, ECPs caused a drop in RBC and Hb, a raise in ALT, AST, BUN, and CREA, and extended PT、TT、APTT, and was found significant difference (P<0.01, P<0.05). When the convalescence is over (in the15th week), all the other indicators mentioned above, except ALT and AST, basically recovered to their normal level. Comparison among the groups of the same period with the same treatment but different dose level:significant differences were found between the high dose group and the low dose group.Comparison among the groups of the same period with the same dose level but different treatment:In the level of low dose, no differences was found having statistical sense; In the level of high dose, Significant differences were found in ALT、AST、BUN、CREA、PT、APTT between the head&foot group and the holo-centipede group, and between the head&foot group and the trunk group(P<0.01, P<0.05);but no difference was found between the holo-centipede group and the trunk group(P>0.05).③Pathological examination:After the experiment, the rats were killed and pathological examination was made on them. The results show that the groups of any dose level have no significant influence on organ coefficient. During the administration, high dose of head&foot extract, holo-centipede extract, and trunk extract caused swelling in the liver cells, especially the high dose of head&foot extract even caused liver necrosis, and mild cellular edema in kidney. When the convalescence was over, the damage on liver and kidney was reduced, the kidney basically recovered, hepatic necrosis remained. None group made significant damage on the rats' heart, brain, lung or spleen.
(3)Genetic toxicity test:①Micronucleus test:No significant deviation was found in micronucleus rate between all the groups lavaged with ECPs and their negative contrast groups (P>0.05); while high significant deviation was found between cyclophosphamide positive contrast group and negative contrast group (P<0.01). This shows that the ECPs have no effect on proliferation of mice polychromatic erythrocytes.②Sperm Malformation Test:No manifest effect by the ECPs was found on the sperm malformation of the mice; no significant deviation was found in any group (at different dose level) compared with their negative contrast group (P>0.05); and significant deviation was found in the positive control group compared with the negative contrast group (P<0.01). This shows that the ECPs have no effect on sperm malformation.③Ames test: The number of colony with back mutation in the positive contrast group exceeded the twice number of that in the negative contrast group; the number of colony with back mutation in varied strains of Salmonella typhimurium at different doses did not exceed the twice number of those with spontaneous mutation. The result of the test was negative.
Conclusion:①Extract from head&foot of centipedes had low toxicity, while the toxicity of extract from holo-centipede is similar to that of the trunk.②When at the same dose level, toxicity of ECPs is:head&foot extract>holo-centipede extract>trunk extract.③ECPs can cause dysfunction in liver, kidney, and coagulopathy; the main target organs may be liver, kidney, etc., while more damage will be caused on liver, and less on kidney and hematological system.④No genetic toxicity of ECPs was found under our experiment condition.⑤It is advisable to use holo-centipede, and to increase the dose appropriately in the clinical treatment of HCC.
Chapter Three:Experimental study on mechanisms of hepatotoxical damage in rats caused by ECPs
Objective:To probe into the toxicological mechanism of ECPs on liver damage through detecting the level of MDA, SOD, CytP450, TNF-α, and IL-6in the livers of SD rats.
Method:The MDA contents in livers were measured by the method of thiobarbituric acid reaction (TBA); the SOD activity of the livers was measured by Xanthine oxidase; the CytP450contents in livers were measured by Omura; TNF-a and IL-6in livers were measured by ELISA.
Result:Compared with the contrast group of the same period, it was found that, during the period of administration, ECPs caused a drop in SOD and CytP450, a raise in MDA, IL-6, TNF-α (P<0.01, P<0.05).When the convalescence is over, all the other indicators mentioned above, except IL-6and TNF-α, basically recovered to their normal level. Comparison among the groups of the same period with the same treatment but different dose level:significant differences were found between the high dose group and the low dose group.Comparison among the groups of the same period with the same dose level but different treatment:Significant differences in MDA. SOD. CytP450、TNF-α、IL-6were found between the head&foot group and the holo-centipede group, and between the head&foot group and the trunk group(P<0.01, P<0.05),but no significant difference was found between the holo-centipede group and the trunk group (P>0.05).
Conclusion:①ECPs can cause a raise in MDA contents and a drop in SOD activity, and may cause a chemical injury in liver cells through lipid peroxidation.②ECPs can cause a raise in TNF、IL-6contents and immunological injury in liver cells through inducing cytokine and inflammatory factors (such as TNF, IL-6,etc.).③ECPs can cause a drop in CytP450contents in liver, and the damage may be caused through affecting Histamine-HP450in the animals'body.
引文
[1]Parkin DM, Bray F, Ferlay J,et al. Global cancer statistics,2002[J]. CA Cancer J Clin,2005,55(2):74-108.
[2]中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治的专家共识[J].胃肠病学和肝病学杂志,2009,18(6)：483-492.
[3]吴孟超.肝癌外科治疗的近期进展[J].中国普外基础与临床杂志,2006,13(2)：125-128.
[4]Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma:Conclusions of the Barcelona-2000 EASL Conference[J].J Hepatol,2001, 35(2):421-430.
[5]韩芳.中医药治疗原发性肝癌的研究进展[J].湖北中医学院学报,2010,12(2)：63-65.
[6]韩双红.蜈蚣的研究进展[J].天津药学,2002,14(5)：13-15.
[7]谭复成.蜈蚣的药理作用及应用[J].现代医药卫生2006,22(13)：2031-2032.
[8]房广星,耿辉.蜈蚣临床应用研究进展[J].山东中医药,2004,23(8)：509-510.
[9]迟萍,迟程,牛祖智.蜈蚣验方治百病[J].中国民族民间医药杂志,1996,21：23-30.
[10]张丽民,郝蕾,王月梅.蜈蚣与全蝎在中医外科中的应用[J].湖北中医杂志,2002,24(4)：43.
[11]田雪飞,肖竺,郭永良,等.归肝经中药对肝癌HepG2细胞增殖抑制及调亡诱导作用研究[J].中国中西医结合急救杂志,2009,16(4)：199-202.
[12]刘国清,田秉漳,皮执民,等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[13]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖北中医杂志,2004,20(5)：57-58.
[14]曲爱兵,赵维诚,梁良,等.蜈蚣组织提取物抗肿瘤活性的初步研究[J].实用肿瘤学杂志,2003,17(1)：29-30.
[15]李风云,陈浩然,张蓄兰,等.中药制剂抗肿瘤作用的实验研究[J].中医药学报,1999,27(5)：57.
[16]孙婧,田雪飞.四味归肝经虫类中药对肝癌HepG2细胞增殖抑制作用对比研究[J].中国中医药现代远程教育,2010,8(16)：161-162.
[17]刘细平,陈宏伟,钟德玝.蜈蚣提取液对肝癌Bel-7404细胞体外抗癌作用的研究[J].现代中西医结合杂志,2009,18(32)：3935-3938.
[18]刘细平,钟德玝.蜈蚣提取液对裸鼠移植肝癌治疗作用研究[J].现代中西医结合杂志,2010,19(15)：1842-1844.
[19]刘细平,钟德玝.蜈蚣提取液对裸鼠移植肝癌抑癌作用及机制的研究[J].中国普通外科杂志,2010,19(2)：164-168.
[20]刘翔峰.蜈蚣醇提液的毒理学研究及对肝癌细胞株Bel-7402生物学影响[博士学位论文].长沙：中南大学,2008.
[21]吴刚,冉永禄,迟程,等.少棘巨蜈蚣的化学组成[J].动物学研究,1991,12(3)：319.
[22]冉永禄,吴刚,叶文娟,等.墨江蜈蚣与少棘蜈蚣的比较研究-化学成分[J].动物学研究,1995,16(4)：379-383.
[23]方红,邓芬,王克勤.多棘蜈蚣化学成分的研究[J].中国药学志,1997,32(4)：202-204.
[24]方红,邓芬,严宜昌,等.黑头蜈蚣的化学成分[J].中药材,1999,22(5)：226-228.
[25]唐宁群,邹长英.对蜈蚣毒性与用量的疑义[J].中医药研究,1999,15(4)：59.
[26]王克勤,陈厚祥,方红,等.药用蜈蚣源流考[J].时珍国药研究,1997,8(5)：385-386.
[27]焦波,娄红祥,王东兴,等.蜈蚣提取液对小鼠精原细胞的作用[J].山东医科大学学报,1999,37(4)：358.
[28]胡卫,陈涛.鼠移植性肝癌模型研究进展[J].河南肿瘤学杂志,2003,16(6)：463-465.
[29]周立国,主编.药物毒理学(第1版)[M].湖北：湖北科学技术出版社,2001,283.
[30]国家药典委员会,编.中华人民共和国药典[M].北京：化学工业出版社,2000,第一版,294.
[31]Iwanuma Y,Chen F, Egilmez N, et al. Antitumor immune response of human periperal blood lymphocytes coengrafted with tumor into severe combined immmunodeficient mice [J].Cancer Res,1997,57(14):2937-2942
[32]宋萍,王学美,谢爽,等.鲜壁虎冻干粉抑制H22肿瘤血管生成机理的实验研究[J].中国中西医结合杂志,2006,26(1)：58-62.
[33]彭方兴,严律南.肝癌动物模型的研究进展[J].中华实验外科杂志,17(5)：475-476.
[34]徐静,李旭.肝癌动物模型的建立[J].实用肝脏病杂志,2005,8(2)：116-118.
[35]杨继金,朱永法,左长京,等.大白鼠转移性肝癌模型的制作[J].中华放射学杂志,1993,27：122-123.
[36]Jimbo T, Akimoto T, Tohgo A.Systemic administration of a synthetic lipid A derivative, DT-5461a, reduces tumor blood flow through endogenous TNF production in hepatic cancer model of VX2 carcinoma in rabbits[J]. Anticancer Res.1996,16(1): 359-364.
[37]Kuwata Y, Hirota S, Sako M.Treatment of metastatic liver tumors by intermittent repetitive injection of an angiogenesis inhibitor using an implantable port system in a rabbit model[J]. Kobe J Med Sci.1997,43(2):83-98.
[38]Celinski SA,Fisher WE,Amaya F,et al.Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts[J].J Surg Res,2003,115:41-47.
[39]叶燕丽,周听熙,王莲桂.裸鼠的繁殖及在肿瘤学中的应用[J].实验动物科学与管理,2005,22：6-8.
[40]Yao X,Hu JF,Daniels M,et al.A novel orthotopic tumor model study growth factors and oncogenes in hepatocarcinogenesis[J].Clin cancer Res,2003,9:2719-2726.
[41]何生,薛华.原发性肝癌治疗现状与评价[J].肝胆外科杂志,2000,8(3)：162-164.
[42]吴孟超.中医药在治疗肝癌中的地位、作用和存在的问题[J].中西医结合学报,2003,1(3)：163.
[43]蒋莲秀,赵一.常用治疗肝癌中药及作用机制研究进展[J].广西中医学院学报,2005,8(2)：73-76.
[44]郑界勋.以毒攻毒中药治疗原发性肝癌的文献研究[J].承德医学院学报,2009,26(1)：47-50.
[45]肖竺,田雪飞.单味中药抗肝癌实验研究进展[J].中国中医药信息杂志,2008,15(1)：100-102.
[46]钟毅,周红,伍耀衡,等.刘伟胜教授运用全蝎、蜈蚣治疗恶性肿瘤经验[J].新中医,2001,33(7)：7.
[47]张娟.焦中华治恶性肿瘤蜈蚣配伍经验[J].山东中医杂志,1999,18(9)：419-420.
[48]LaVallie ER, DiBlasio EA, Kovacic S, et al. A thiore-doxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm[J]. Bioteohnology (NY),1993,11(2):187-193.
[49]邓芬,方红,王克勤.中药蜈蚣毒溶血活性试验[J].中药材,1997,20(1)：36.
[50]安胜利,莫一心,欧春泉.在SPSS10.0软件上进行概率单位分析[J].第一军医大学学报,2002,22(11)：1019-1021.
[51]熊国娟,刘敏.临床应用蜈蚣不宜去头[J].时珍国医国药,2001,12(11)：983.
[52]冉永禄,吴刚,王金焕,等.墨江蜈蚣与少棘蜈蚣的比较研究-药效与毒理[J].动物学研究,1996,17(1)：79-83.
[53]张智,闪增郁,向丽华,等.15味有毒中药小鼠半数致死量的实验研究[J].中国中医基础医学杂志,2005,11(6)：435-436.
[54]中华人民共和国国家药品监督管理局.化学药物长期毒性研究技术指导原则,2005.3.
[55]中华人民共和国国家药品监督管理局.中药、天然药物长期毒性研究技术指导原则,2005.3.
[56]陈文彬,主编.诊断学(第5版)[M].北京：人民卫生出版社,2001,403.
[57]刘峰.蜈蚣的临床应用及其毒性研究[J].广西中医药,1999,22(4)：52-53.
[58]王家鹏,郭刚,王冉.“以毒攻毒”法治疗恶性肿瘤的现代研究[J].中医药学刊,2003,21(12)：2075-2076.
[59]吴良村,成文武,郭勇,等.吴良村中西医治疗原发性肝癌经验[J].浙江中医学院学报,2000,4：57.
[60]王庆才,李道明.王庆才治疗肝癌经验[J].辽宁中医药杂志,2000,9：395-397.
[61]司春富,谢有良.应用化疗法治疗肝癌的研究进展[J].河南中医,1999,10(60)：35-38.
[621苑淑芳,张俊富.病毒性肝炎肝硬化中医分型与肝癌血清学指标的关系[J].天津中医杂志,1997,14(3)：102-104.
[63]张存义,钱心兰.扶正祛邪法治疗肝癌之体会[J].上海中医药杂志,2000,11：22-23.
[64]傅凤霞,张正芳,王琦.原发性肝癌手术后辨证治疗60例[J].南京中医药大学学报,1997,13(5)：314-315.
[65]中华人民共和国卫生部/中国国家标准化管理委员会.GB15193.5-2003.中华人民共和国国家标准-骨髓细胞微核试验.北京：中国标准出版社,2003-09-24.
[66]中华人民共和国卫生部/中国国家标准化管理委员会.GB15193.7-2003.中华人民共和国国家标准-小鼠精子畸形试验.北京：中国标准出版社,2003-09-24.
[67]中华人民共和国卫生部/中国国家标准化管理委员会.GB15193.4-2003.中华人民共和国国家标准-鼠伤寒沙门氏菌/哺乳动物微粒体酶试验.北京：中国标准出版社,2003-09-24.
[68]肖凯,李宏霞.遗传毒性试验方法应用现况与研究进展[J].现代预防医学,2004,31(4)：524-526.
[69]中华人民共和国国家质量监督检验检疫总局.GB15193.1-2003.中华人民共和国国家标准-食品安全性毒理学评价程序.北京：中国标准出版社,2005-01-01.
[70]Elisabeth L, Carine L, Veronique G, et al. Genetic Toxicity Assessment:Employing the Best Science for Human Safety Evaluation Part Ⅱ:Performances of the In Vitro Micronucleus Test Compared to the Mouse Lymphoma Assay and the In Vitro Chromosome Aberration Assay[J]. Toxicol Sci,2007,96:214-217.
[71]李寿祺,主编.卫生毒理学基础[M].人民卫生出版社,2004.
[72]范瑞泉,魏青,丘钦英,等.小鼠精子畸形试验改良法与传统法效果比较[J].华南预防医学,2004,30(2)：51-52.
[73]Ames BN,Mccann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test[J].Mutat Res,1975,31 (6):347-364.
[74]楼宜嘉,主编.药物毒理学(第2版)[M].北京：人民卫生出版社,2008,206.
[75]王心如,主编.毒理学基础(第5版)[M].北京：人民卫生出版社,2007,28.
[76]关建红,翁维良.对中药“毒性”与毒性分级的思考[J].中国中药杂志,2008,33(4)：485-487.
[77]杨仓良,主编.毒药本草[M].北京：中国中医药出版社,1993,14.
[78]翁维良.临床中药不良反应的探讨[J].中药新药与临床药理,1996,7(2)：4.
[79]杜贵友,方文贤.有毒中药现代研究和合理应用[M].北京：人民卫生出版社,2003.
[80]袁伯俊,王治乔,主编.新药临床前安全性评价与实践[M].北京：军事医学出版社,1997.
[81]周程,胡思安,龚昭,等.胆囊癌对化疗药物敏感性的研究[J].中年现代外科学杂志,2005,2(20)：1830-1832.
[82]宋晓伟,康健,林滢.改良的考马斯亮兰G250染色法简便快速测定微量蛋白浓度[J].洛阳医专学报,1997,16(3)：150-152.
[83]杨李,唐瑛,左娟,等.硫代巴比妥酸法测定血清脂质过氧化物方法的改进[J].华南国防医学杂志,2004,18(1)：30-32.
[84]张凤翔.黄嘌呤氧化酶氧化酶法测定血清中超氧化物歧化酶活力的影响因素[J].云南医药,2001,22(6)：473-474.
[85]林志彬,金有豫.药理学实习教程[M].世界图书出版公司,1989：73-77.
[861李娟,张耀庭,曾伟,等.应用考马斯亮兰法测定总蛋白含量[J].中国生物制品学杂志,2000,13(2)：118-120.
[87]徐叔云,主编.药理实验方法学[M].北京：人民卫生出版社,2002：514-515.
[88]谢青,赵钢德.肝细胞损伤分子生物学机制[J].中华肝脏病杂志,2008,16(9)：211-213.
[89]刘丹卓,赵新广.肝损伤病因病理机制及中医药治疗研究近况[J].国医论坛2006,21(6)：53-55.
[90]李艳辉,肖恩华.实验性肝损伤模型的建立和评价[J].放射学实践,2006,21(10)：1075-1077.
[91]汤新慧,高静.实验性肝损伤的损伤机制[J].中西医结合肝病杂志,2002,12(1)：53-55.
[92]苏俊芳,林铭育,李常青.抗纤软肝方对刀豆蛋白A致小鼠免疫性肝损伤的保护作用[J].中国热带医学,2008.8(7)：1094-1095.
u D, Thiele GM, Beckenhauer JL, et al. Detection of circulating antibodies to malondialdehyde-acetaldehyde adducts in ethanol-fed rats[J].Gastroenterology,1998, 115(3):686-692.
[941Rigamonti C, Mottaran E, Reale E, et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C[J]. Hepatology,2003,38(1):42-49.
[95]Vidali M, Hietala J, Occhino G, et al.Immune responses against oxidative stress-derived antigens are associated with increased circulating tumor necrosis factor-alpha in heavy drinkers[J]. Free Radic Biol Med,2008,45(3):306-311.
[96]杨牧祥,张一听,王少贤,等.柔肝消癥饮对肝硬化大鼠血清和肝组织IL-p、IL-6和TNF-a的影响[J].中华中医药杂志,2007,22(10)：729-731.
[97]Reinhart K, Menges T, Gardlund B, et al.Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis:the RAMSES Study [J]. Crit Care Med,2001,29,765-769.
[98]Roberto PF, Lindholm B, Axelsson J, et al. Update on interleukin-6 and its role in chronic renal failure [J]. Nephrol Dial Transplant,2003,18:1042-1045.
[99]姚光弼.药物性肝病[J].中华消化杂志,1999,19(5)：339-342.
[100]Fukui H, Wang NP, Watanabe T, et al.Solubilization, characterization and partial purification of [3H]mepyramine-binding protein, a possible histamine H1 receptor, from rat liver membrane[J]. Jpn J Pharmacol,1988,46(2):127-139.
[101]臧林泉,王乃平.肝脏中的细胞色素P-450与组胺受体[J].中国药理学通报,1993：9(6)：414-417.
[102]Mizuguchi H,Liu YQ,Fukui H,et al. Soludilization and characterization of H1 receptor in rat liver[J]. Jan J Pharmacal,1989,52(Suppl):180.
[103]Wang NP,Zhang LQ,Huang RB,et al.Determination of age-related changes of cytochrome P450 sensitive to mepyramine in rat hepatic microsomes[J].Acta Pharmaceutica Sinica,1995,30(10):726-730.
[104]方红,邓芳.蜈蚣药材中毒性成分组织胺的含量测定[J].中草药,1997,28(8)：472-473.
[105]陈继康,王言斌,张莉.鱼类组织胺含量测定及鲐巴鱼去组织胺的实验监测报告[J].中国卫生检疫杂志,2003,13(1)：98.
[106]孙黎黎,薛丰松.鱼类组织胺含量测定方法的改进[J].预防医学论坛,2005,11(2)：196-198.
[107]韶衡,李萍.肥大细胞激活及组织胺水平测定[J].华西医科大学学报,2002,33(4)：586-588.
[108]金成洙,吴龙仁,朴红心,等.磷酸组织胺诱导的I型超敏反应对肝损伤作用的研究[J].中国免疫学杂志,2007,12(23)：1140-1141.
i MA,Nassar SH,EI-Bassiouni EA,et al. Histamine and histamine receptor antagonists in splanchnic compartments in schistosomal portal hypertension[J]. Clin Pharmacol Ther,1988,44:396-405.
TF. Free radical mechanisms in tissue injury[J]. Biochem J,1984,222:1.
[1]张崇洲,土克勤.两种药用蜈蚣的简介[J].动物学杂志,1995,30(4)：51-54.
[2]王克勤,方红,叶卯祥.蜈蚣药源调查及商品鉴定[J].中药材,1997,20(9)：450-451.
[3]王克勤,陈厚祥,方红,等.药用蜈蚣源流考[J].时珍国药研究,1997,8(5)：385-386.
[4]国家药典委员会,编.中华人民共和国药典[M].北京：化学工业出版社,2000,第一版,294.
[5]唐宁群,邹长英.对蜈蚣毒性与用量的疑义[J].中医药研究,1999,15(4)：59.
[6]熊国娟,刘敏.临床应用蜈蚣不宜去头[J].时珍国医国药,2001,12(11)：983.
[7]江苏新医学院.中药大辞典·下册[M].上海：上海科学技术出版社,1986,2474.
[8]王端玲,程久菊.对临床应用蜈蚣的建议[J].中国药学杂志,1999,34(6)：393.
[9]迟程,罗天浩.蜈蚣毒性与用量的探讨[J].中国中药杂志,1995,15(6)：90.
[10]宋建徽,孟祥琴,王永利,等.蜈蚣提取物中枢抑制作用及急性毒性[J].河北医学院学报,1995,16(2)：90.
[11]李小莉,陈红琳,甘民.不同品种蜈蚣的抗炎、镇痛作用[J].中国中药杂志,1996,21(8)：498.
[12]周宜强.攻毒、排毒、解毒在治疗恶性肿瘤中的运用[J].世界中医药,2007,2(4)：200-2003.
[13]李向东.蜈蚣浅析新论[J].实用医技杂志,1996,3(7)：506.
[14]毛小平,陈子君,毛晓建,等.蜈蚣的部分药理研究[J].云南中医学院学报,1999,22(3)：1-4.
[15]李厚伟,张妍,许超千,等.中药HB对喉癌Hep22细胞的抑制作用及其机制研究[J].哈尔滨医科大学学报,2001,35(4)：261-262.
[16]曲爱兵,赵维成,梁良,等.蜈蚣组织提取物抗肿瘤活性的初步研究[J].实用肿瘤学杂志,2003,17(1)：29-30.
[17]许鸣镝,柳雪枚.蜈蚣碱性蛋白SSmp-d的分离纯化及其部分理化性质的鉴定[J].生物化学杂志,1997,13(5)：586-591.
[18]王贤纯.蜈蚣的药用研究进展[J].动物学杂志,2002,37(3)：88-91.
[19]刘国清,田秉漳,皮执民,等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[20]焦波,娄红祥,王东兴,等.蜈蚣提取液对小鼠精原细胞的作用[J].山东医科大学学报,1999,37(4)：358.
[21]李风云,陈浩然,张蓄兰,等.中药制剂抗肿瘤作用的实验研究[J].中医药学报,1999,27(5)：57.
[22]刘德贵,苗艳波,张铁光,等.简述有毒动物药的抗肿瘤作用临床研究[J].吉林中医药,1998,18(6)：61.
[23]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖南中医杂志,2004,20(5)：57-58.
[24]黄金昶.“以毒攻毒”“温阳”“破淤”“通利二便”四法治疗肿瘤之我见[J].中国临床医生,2005,33(10)：51-52.
[25]孙谊,于智敏.“以毒攻毒”探源[J].中国中医基础医学杂志,2008,14(8)：584-585.
[26]陈士奎.“以毒攻毒”与中西医结合研究[J].医学与哲学,1998,19,4：186-187.
[27]王家鹏,郭刚,王冉.“以毒攻毒”法治疗恶性肿瘤的现代研究[J].中医药学刊,2003,21(12)：2075-2076.
[28]迟程,牛祖智.蜈蚣验方治百病[J].中国民族民间医药杂志,1996,21：23-30.
[29]薛功友,黄建华.济生颗粒加减治疗30例中晚期肺癌的临床研究[J].中国中医基础医学杂志,1999,5(2)：38-39.
[30]黄金昶,贾立群.“以毒攻毒”方药治疗恶性肿瘤[J].中日友好医院学报,2000,14(2)：117-120.
[31]李远东,张连新.中药散剂治疗肿瘤疼痛[J].中国民间疗法,1996,(1)：9.
[32]吴刚.蜈蚣毒的化学组成和生物活性[J].生物化学杂志,1992,8(2)：144.
[33]方红,邓芳.蜈蚣药材中毒性成分组织胺的含量测定[J].中草药,1997,28(8)：472.
[34]邓芬,方红,王克勤.中药蜈蚣毒溶血活性试验[J].中药材,1997,20(1)：36.
[35]左传田,祝家兴.组胺及其受体与原发性肺癌[J].实用肿瘤杂志,2000,15(2)：143-145.
[36]Grimbaldeston MA, Green A, Darlington S, et al. Susceptibility to basal cell carcinoma is associated with high dermal mast cell prevalence in non-sun-exposed skin for an Australian populations [J].Photochem Photobio,2003,78(6):633-639.
[37]Wan NP, Zang LQ, Huang RB, et al.The assay of antinlstamlnergic sensitive cytochrome p450 in rats[J]药学学报,1995,30(10)：726-730.
[38]Burtin C, Noirot C, Paupe J,et al. Decreased blood histamine levels in patients with solid malignant tumours[J]. Br J Cancer,1983,47(3):367-372.
[39]Burtin C, Noirot C, Giroux C, et al.Decreased skin response to intradermal histamine in cancer patients[J]. Allergy Clin Immunol,1986,78(1 Pt 1):83-89.
[40]Johansson M, Henriksson R, Bergenheim AT, et al.Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis inmalignantglioma[J]. Br J Cancer,2000,83(6):826-832.
[41]Rizell M,Hellstrand K,Lindner P,et al.Monotherapy with histamine dihydrochloride suppresses in vivo growth of a rat sarcoma in liver and subcutis [J]. Anticancer Res, 2002,22(4):1943-1948.
[42]Ohuchi Y, Yanai K, Sakurai E, et al. Histamine-induced calcium mobilization in single cultured cells expressing histamine H1 receptors:a relationship between its sensitivity and the density of H1 receptors [J]. J Mol Med,1998,1(2):355-360.
[43]Hellstrand K,Hansson M,Hermodsson S.Adjuvant histamine in cancer immuno-therapy[J]. Seminars in Cancer Biology,2000,10(1):29-39.
[44]Adams WJ, Lawson JA, Morris DL. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth[J]. Gut 1994,35:1632-1636.
[45]Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cell-mediated resistance against tumor cells[J]. J Immunol,1990,145(12):4365-4370.
[46]Johansson S, Landstrom M, Hellstrand K, et al.The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation[J]. Br J Cancer.1998,77(8): 1213-1219.
[47]曹漫明,汪森明,张积仁,等.组胺/IL-2联合激活的骨髓对移植物中肿瘤细胞的净化[J].癌症,2001,20(12)：1434-1435.
[48]Johansson M, Henriksson R, Bergenheim AT, et al.Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma[J].Br J Cancer,2000,83(6):826-832.
[49]Johansson S, Landstrom M, Henriksson R. Alterations of tumour cells, stroma and apoptosis in rat prostatic adenocarcinoma following treatment with histamine, interleukin-2 and irradiation[J]. Anticancer Res,1999,19(3A):1961-1969.
[50]何邦平,陈杰,张欣荣,等.微量元素与人体健康关系研究的回顾与展望[J].生命科学仪器,2003,1(1)：41-44.
[51]段飞,李发荣,杨建雄.微量元素与中药[J].陕西师范大学学报(自然科学版),2004,32：184-186.
[52]徐兆森,邵俭.微量元素与中药[J].辽宁药物与临床,2000,3(4)：182-184.
[53]冉永禄,吴刚,叶文娟,等.墨江蜈蚣与少棘蜈蚣的比较研究一Ⅰ化学组成[J].动物学研究,1995,16(4)379-383.
[54]姚惠英,曾宪周,卢成荣,等.肿瘤病人头发中微量元素的PIXE分析[J].中华肿瘤杂志,1988,10(2)：92.
[55]王智兴,张沪生,叶衍庆,朱世盛.骨巨细胞瘤瘤组织11种元素分析[J].肿瘤,1994,14(3)：149.
[56]闵锐.微量元素与血液系统某些恶性疾病的关系[J].国外医学输血及血液学分册,1989,12(2)：65.
[57]田柱萍,何邦平,王小燕,等.中药材的药效与其所含微量元素关系的研究进展[J].微量元素与健康研究,2005,22(4)：54-56.
[58]王亚丽.微量元素与中药抗癌[J].甘肃中医,1998,11(5)：43-44.
[59]Negri A,Llewellyn L.Comparative analyses by HPLC and the sodium channel and saxiphilin3H-saxitoxin receptor assays for paralytic shellfishtoxins in crustaceans and molliusks from tropical North West Australia[J].Toxicon,1998,36(2):283-298.
[60]Llewellyn L,Doyle J.Microtitre plate assays for paralytic shellfish toxins using saxiphilin,gauging the effects of shellfish extractmatrices,salts and pH upon assay performance[J].Toxicon,2001,39(2-3):217-224.
[1]Parkin DM,Bray F, Ferlay J,et al. Global cancer statistics[J].Cancer Clin, 2005,55:74-108.
[2]吴孟超.肝癌外科治疗的近期进展[J].中国普外基础与临床杂志,2006,13(2)：125-128.
[3]李连弟,张思维,鲁凤珠,等.中国恶性肿瘤死亡谱及分类构成特征研究[J].中华肿瘤杂志,1997,19：323-328.
[4]龚新雷,秦叔逵.原发性肝癌的分子靶向治疗研究新进展[J].临床肿瘤学杂志,2008.13(1)：1-9.
[5]Bismuth H, Morino M, Sherlock D, et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization[J].Am J Surg,1992,163(4):387-394.
[6]Livraghi T, Lazzaroni S, Meloni F,et al. Intralesional ethanol in the treatment of unresectable liver cancer [J].World J Surg,1995,19(6):801-806.
[7]Sitzmann JV. Conversion of unresectable to resectable liver cancer:an approach and follow-up study[J].World J Surg,1995,19(6):790-794.
[8]Farmer DG, Rosove MH, Shaked A, et a/.Current treatment modalities for hepatocellular carcinoma[J].Ann Surg,1994,219(3):236-247.
[9]Ono Y, Yoshimasu T, Ashikaga R,et al.Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma[J]. Am J Clin Oncol.2000,23(6):564-568.
[10]何生,薛华.原发性肝癌治疗现状与评价[J].肝胆外科杂志,2000,8(3)：162-164.
[11]Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma [J]. J Clin Oncol,2003,21(3):421.
[12]Feun L G, O'Brien C, Molina E, et al. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patient s wit h hepatocellular carcinoma-A phase Ⅱ trial [J]. J Cancer Res Clin Oncol,2003,129(1):17.
[13]Leung TW, Part YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma [J]. Clin Cancer Res,1999,5(7):1676.
[14]Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy [J].Cancer, 2002,94(2):421.
[15]中国抗癌协会肝癌专业委员会.原发性肝癌规范化诊治的专家共识[J].胃肠病学和肝病学杂志,2009,1(6)：483-492.
[16]王中堂,李宝生,闰婧,等.原发性肝癌三维适形放疗后放射性肝病的相关因素分析[J].中华放射肿瘤学杂志,2007,16：281-285.
[17]Li B, Yu J, Wang L, Li C, et al. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma[J]. Am J Clin Oncol,2003,26(4):e92-99.
[18]Liu MT, Li SH, Chu TC, et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization[J]. Jpn J Clin Oncol,2004(9),34:532-539.
[19]Cheng JC, Chuang VP, Cheng SH, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys,2000,47(2):435-442.
[20]Liang SX, Zhu XD, Lu HJ, et al.Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma[J].Cancer,2005,103(10):2181-2188.
[21]Kim TH, Kim DY, Park JW, et al.Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable [J]. Am J Clin Oncol,2006,29(6): 568-575.
[22]陆东东,陆培新.原发性肝癌的药物治疗进展[J].新医学,2001,32(4)：235-237.
[23]史仲华,郭彦君,刘德忠,等.132例原发性肝癌灌注化疗及栓塞治疗疗效观察[J].中华肿瘤杂志,1999,21(3)：211.
[24]Lu CL, Wu JC, Chiang JH, et al. Hepatocellular carcinoma in the caudate lobe: early diagnosis and active treatment may result in long-term survival [J].J Gastroenterol Hepatol,1997,12(2):144-148.
[25]刘康达,陆继珍,谭文翔,等.肝癌的门静脉血供研究及栓塞治疗[J].中华医学杂志,1995,75(7)：403-405.
[26]茅国新,于志坚,张一心,等.经导管肝动脉和B超引导下经细针门静脉双重化疗栓塞治疗原发性肝癌[J].中华肿瘤杂志,2002,24(4)：391-393.
[27]Gaiani S,Celli N,Cecilioni L,et al.Review article:percutaneous treatment of hepatocellular carcinoma[J].Aliment Pharmacol Ther,2003,17(Suppl2):103-110.
[28]Livraghi T, Benedini V.Lazzaroni S, et al. Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma [J]. Cancer,1998,83(1):48-57.
[29]Arii S,Yamaoka Y,Futagawa S,et al.Result of surgical and nonsurgicai treatment for Small-sized hepatollular carcinoma:A retrospective and nationwide survey in Japan[J].Hepatology,2000,32(6):1224-1229.
[30]吴孟超,吴东.原发性肝癌的外科治疗进展[J].临床外科杂志,2005,13(1)：4-7.
[31]Khan KN, Yatsuhashi H, Yamasaki K, et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection[J] J Hepatol,2000,32:269-278.
[32]Livraghi T, Benedini V, Lazzaroni S, et al. Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma[J]. Cancer,1998,83(1):48-57.
[33]庄振武,高雨东,李麟荪.超声导引经皮肝内注射乙酸的初步实验研究[J].南京医科大学学报,1997,17：457.
[341李拾林,吕国荣,李新丰.肝内注射致坏死剂的实验研究[J].中华超声影像学杂志,2000,9(8)：511.
[35]Garcea G, Lloyd TD, Aylott C, et al. The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours[J].Eur J Cancer,2003(15),1-15.
[36]Tamai T, Seki T, Imamura M,et al. Percutaneous injection of a low-concentration alkaline solution targeting hepatocellular carcinoma[J].Oncol Rep,2000,7(4):719-723.
[37]刘利民,张韵华,许根英.氢氧化钠溶液肿瘤瘤内注射的实验研究[J].中国超声医学杂志,2000,16(5)：325.
[38]Honda N, Guo Q, Uchida H, et al.Percutaneous hot saline injection therapy for hepatic tumors:an alternative to percutaneous ethanol injection therapy. Radiology[J].1994,190(1):53-57.
[39]Veltri A, Martina C, Bonenti G, et al.Therapy of malignant hepatic tumors using percutaneous hot saline injections. Feasibility study and preliminary results[J]. Radiol Med.1995,90(4):463-469.
[40]Yoon HK, Song HY, Sung KB, et al.Percutaneous hot saline injection therapy: effectiveness in large hepatocellular carcinoma[J].J Vase Interv Radiol.1999,10(4): 477-482.
[41]Huang JF,Kuang M,Lu M. Percutaneous hyperthermal distilled water injection therapy (PHDT) for liver cancer[J]. Asian J Surg,1999(22):337.
[42]周方平,苏健坤,张铁山,等.超声引导肝内注射高温蒸馏水对肝坏死的实验研究[J].中国临床医学影像杂志.2003,14(2)：137-138.
[43]周方平,苏健坤,王迎春,等.超声引导经皮肝内注射高温蒸馏水致肝坏死的病理学改变[J].医学影像学杂志2003,13(6)：422-423.
[44]叶胜龙.原发性肝癌非手术治疗的评价[J].中华肝脏病杂志,2003,11(12)：709-711.
[45]Rossi S, Buscarini E, Garbagnati F, et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode[J]. Am J Roentgenol,1998,170:1015-1022.
[46]Solbiati L, Goldberg SN, Ierace T, et al. Hepatic metastases:percutaneous radiofrequency ablation with cooled-tip electrodes[J].Radiology,1997,205:367-373.
[47]Livraghi T. Goldberg SN.Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection[J]. Riadiology, 1999,210(3):655-661.
[48]Dong B,Liang P,Yu X,et al.Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma:results in 234patients[J].Am J Roentgenol,2003,180(6):1547-1555.
[49]Itamoto T, Katayama K, Fukuda S, et al. Percutaneous microwave coagulation therapy for primary or recurrent hepatocellular carcinoma:long-term results [J] Hepatogastroenterology,2001,48(41):1401-1405.
[50]吕明德,陈俊伟,谢晓燕,等.超声引导瘤内高温治疗肝癌细胞癌[J].中华外科杂志,2001,7：502-504.
[51]Seki S, Sakaguchi H, Kadoya H, et al. Laparoscopic microwave coagulation therapy for hepatocellular carcinoma [J].Endoscopy,2000,32(8):591-597.
[52]Giorgio A, Tarantion L, de Stefano G, et al. Interstitial laser photocoagulation under ultrasound guidance of liver tumors:results in 104 treated patients[J].Eur J Ultrasound,2000,11(3):181-188.
[53]梁萍,董宝玮,顾瑛,等Nd:YAG激光热凝固肝组织的实验研究及肝癌治疗应用[J].中华理疗杂志,1999,22：158-160.
[54]Pacella CM, Bizzarri G, Cecconi P, et al. Hepatocellular carcinoma:long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization [J].Radiology,2001,219(3):669-678.
[55]周信达,汤钊猷,余业勤,等.液氮局部冷冻治疗肝癌[J].实用肿瘤杂志,1995,10：140-141.
[56]张保宁,张叔人,曲平,等.围冷冻手术期施行免疫疗法的抗肿瘤作用[J].中华肿瘤杂志,1999,21：427-428.
[57]郭发金,杨杨,张永强.高强度聚焦超声治疗肝癌的近期疗效评价fJ].中国医学影像技术,2004,20(2)：279-281.
[58]罗荣城,韩焕兴.肿瘤生物治疗学[M].北京：人民卫生出版社,2006：304.
[59]Atarashi Y, Yasumura S,Nambu S,et al. A novel human tumor necrosis factor alfa mutein, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma:implication for immunotherapy of human hepatocellular carcinoma[J]. Hepatology,1998,28(1):57-67.
[60]Kubo S,Nishiguchi S,Hirohashi K,et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy[J].Br J Surg,2002,89(4):418-422.
[61]Lin SM, Lin CJ, Hsu CW, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors [J].Cancer,2004,100(2):376-382.
[62]Penichet ML,Morrison SL. Antibody-cytokine fusion proteins for the therapy of cancer[J] J Immunol Methods,2001,248(1-2):91-101.
[63]Yajun G,Mengchao W, Han C, et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells[J].Science,1994,263 (5146):518-520.
[64]Chung W L.Natural riller cell activity in patients with HCC relative to early development and tumor invasion[J].Cancer,1996,71(4):926-928.
[65]Iwashita Y, Tahara K, Goto S, et al.A phase Ⅰ study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer[J]. Cancer Immunol Immunother.2003,52(3):155-161.
[66]Palmer DH, Midgley RS, Mirza N, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology[J].2009,49(1):124-132.
[67]Buterfield LH. Immunotherapeutic strategies for hepatocellular carcinoma[J]. Gastroenterology,2004, (5 Suppl 1):S232-241.
[68]Schulze T, Kemmner W, Weitz J, et al. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases:results of a prospective randomized trial[J]. Cancer Immunol Immunother,2009,58(1):61-69.
[69]Lan YH, Li YG, Liang ZW,et al. A DNA vaccine against chimeric AFP enhanced by HSP70 suppresses growth of hepatocellular carcinoma [J]. Cancer Immunol Immunother.2007,56(7):1009-1016.
[70]杨冬华.肝癌的免疫治疗现状及前景[J].中华肝脏病杂志,2003,11(12)：757.
[711钟珍,苏科,周汉新,等.人转铁蛋白修饰载阿霉素海藻酸钠纳米粒的制备与评价[J].中国组织工程研究与临床康复,2010,14(21)：3861-3864.
[72]楼敏.双特异性抗体在肿瘤免疫治疗中的作用[J].国外医学肿瘤学分册,1997,24：212-214.
[73]Takayama T, Sekine T,Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma:a randomised trial [J]. Lancet,2000,356 (9232):802-807.
[74]O'Beirne JP, Harrison PM. The role of the immune system in the control of hepatocellular carcinoma[J].Eur J Gast roenterol Hepatol,2004,16(12):1257-1260.
[751陈孝平,张万广.肝细胞性肝癌实验研究的热点与展望[J].中华实验外科杂志,2006,23(3)：264-265.
[76]Wang XW,Yuan JH,Ghang BG, et al. Antihepatoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxyribonucleotides in vitro and in mice[J]. World J Gastmenterol,2001,7(3):345-351.
[77]Qian C,Drozdzik M,Caselmann WH,et al. The potential of gene therapy in the treatment of hepatocellular carcinoma[J].J Hepatol,2000,32(2):344-351.
[78]Schmitz V,Qian C,Ruiz J,et al. Gene therapy for liver diseases:recent strategies for treatment of viral hepatitis and liver malignancies [J].Gut,2002,50(1):130-135.
[79]Drozdzik M,Qian C, Xie X, et al. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma [J].J Hepatol,2000,32(2):279-286.
[80]Huber BE.Richards CA.Krenitsky TA, et al. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma:an innovative approach for cancer therapy [J]. Proc Natl Acad Sci,1991,88(18):8039-8043.
[81]Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine:a negative selection system[J].Proc Natl Acad Sci,1992,89(l):33-37.
[82]Barajas M,Mazzolini G,Genove G,et al. Gene therapy of orthotropic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12 [J]. Hepatoiogy,2001, 33(1):52-61.
[83]Harada N,Shimada M,Okano S,et al. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice[J].J Immunol,2004,173(11):6635-6644.
[84]Kahlenberg MS, Stoler DL, Basik M, et al. p53 Tumor Suppressor Gene Status and the Degree of Genomic Instability in Sporadic Colorectal Cancers[J]. Journal of the National Cancer Institute,1996,88(22):1665-1669.
[85]Qian C,Drozdzik M,Caselmann WH,et al. The potential of gene therapy in the treatment of hepatocellular carcinoma[J].J Hepatol,2000,32(2):344-351.
[86]Marx J. Angiogenesis:A boost for tumor starvation[J].Science,2003,301(5632): 452-454.
[87]叶义标,陈涛.肝癌血管生成与抗血管生成治疗的研究进展[J].中国普外基础与临床杂志,2009,16(10)：861-865.
[88]McNeish IA, Bell SJ, Lemoine NR.Gene Therapy Progress and Prospects:cancer gene therapy using tumour suppressor genes.Gene Ther,2004,11(6):497-503.
[89]Yoshimura I, Mizuguchi Y, Miyajima A, et al.Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I [J]. J Urol,2004,171(6):2467-2470.
[90]Hotz HG, Hines OJ,Masood R,et al. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer [J].Surgery, 2005,137(2):192-199.
[91]陈慧玲,白海.肿瘤多药耐药的研究进展[J].临床肿瘤学杂志,2008,13(5)：475- 477.
[92]胡礼仪,张有顺,周新,等.MDR短发夹RNA表达质粒的构建及其功能的初步研究[J].肿瘤,2004,24(6)：542-525.
[93]Wu H, Hait WN, Yang JM.Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells [J]. Cancer Res.2003,63(7):1515-1519.
[94]黄金昶.“以毒攻毒”“温阳”“破淤”“通利二便”四法治疗肿瘤之我见[J].中国临床医生,2005,33(10)：51-52.
[95]孙谊,于智敏.“以毒攻毒”探源[J].中国中医基础医学杂志,2008,14(8)：584-585.
[96]陈士奎.“以毒攻毒’”与中西医结合研究[J].医学与哲学,1998,19,4：186-187.
[97]王家鹏,郭刚,王冉.“以毒攻毒”法治疗恶性肿瘤的现代研究[J].中医药学刊,2003,21(12)：2075-2076.
[98]郑界勋.以毒攻毒中药治疗原发性肝癌的文献研究[J].承德医学院学报,2009,26(1)：47-50.
[2]中华医学会肝病学分会肝癌学组.原发性肝癌规范化诊治的专家共识[J].胃肠病学和肝病学杂志,2009,18(6)：483-492.
[3]吴孟超.肝癌外科治疗的近期进展[J].中国普外基础与临床杂志,2006,13(2)：125-128.
[4]Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma:Conclusions of the Barcelona-2000 EASL Conference[J].J Hepatol,2001, 35(2):421-430.
[5]韩芳.中医药治疗原发性肝癌的研究进展[J].湖北中医学院学报,2010,12(2)：63-65.
[6]韩双红.蜈蚣的研究进展[J].天津药学,2002,14(5)：13-15.
[7]谭复成.蜈蚣的药理作用及应用[J].现代医药卫生2006,22(13)：2031-2032.
[8]房广星,耿辉.蜈蚣临床应用研究进展[J].山东中医药,2004,23(8)：509-510.
[9]迟萍,迟程,牛祖智.蜈蚣验方治百病[J].中国民族民间医药杂志,1996,21：23-30.
[10]张丽民,郝蕾,王月梅.蜈蚣与全蝎在中医外科中的应用[J].湖北中医杂志,2002,24(4)：43.
[11]田雪飞,肖竺,郭永良,等.归肝经中药对肝癌HepG2细胞增殖抑制及调亡诱导作用研究[J].中国中西医结合急救杂志,2009,16(4)：199-202.
[12]刘国清,田秉漳,皮执民,等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[13]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖北中医杂志,2004,20(5)：57-58.
[14]曲爱兵,赵维诚,梁良,等.蜈蚣组织提取物抗肿瘤活性的初步研究[J].实用肿瘤学杂志,2003,17(1)：29-30.
[15]李风云,陈浩然,张蓄兰,等.中药制剂抗肿瘤作用的实验研究[J].中医药学报,1999,27(5)：57.
[16]孙婧,田雪飞.四味归肝经虫类中药对肝癌HepG2细胞增殖抑制作用对比研究[J].中国中医药现代远程教育,2010,8(16)：161-162.
[17]刘细平,陈宏伟,钟德玝.蜈蚣提取液对肝癌Bel-7404细胞体外抗癌作用的研究[J].现代中西医结合杂志,2009,18(32)：3935-3938.
[18]刘细平,钟德玝.蜈蚣提取液对裸鼠移植肝癌治疗作用研究[J].现代中西医结合杂志,2010,19(15)：1842-1844.
[19]刘细平,钟德玝.蜈蚣提取液对裸鼠移植肝癌抑癌作用及机制的研究[J].中国普通外科杂志,2010,19(2)：164-168.
[20]刘翔峰.蜈蚣醇提液的毒理学研究及对肝癌细胞株Bel-7402生物学影响[博士学位论文].长沙：中南大学,2008.
[21]吴刚,冉永禄,迟程,等.少棘巨蜈蚣的化学组成[J].动物学研究,1991,12(3)：319.
[22]冉永禄,吴刚,叶文娟,等.墨江蜈蚣与少棘蜈蚣的比较研究-化学成分[J].动物学研究,1995,16(4)：379-383.
[23]方红,邓芬,王克勤.多棘蜈蚣化学成分的研究[J].中国药学志,1997,32(4)：202-204.
[24]方红,邓芬,严宜昌,等.黑头蜈蚣的化学成分[J].中药材,1999,22(5)：226-228.
[25]唐宁群,邹长英.对蜈蚣毒性与用量的疑义[J].中医药研究,1999,15(4)：59.
[26]王克勤,陈厚祥,方红,等.药用蜈蚣源流考[J].时珍国药研究,1997,8(5)：385-386.
[27]焦波,娄红祥,王东兴,等.蜈蚣提取液对小鼠精原细胞的作用[J].山东医科大学学报,1999,37(4)：358.
[28]胡卫,陈涛.鼠移植性肝癌模型研究进展[J].河南肿瘤学杂志,2003,16(6)：463-465.
[29]周立国,主编.药物毒理学(第1版)[M].湖北：湖北科学技术出版社,2001,283.
[30]国家药典委员会,编.中华人民共和国药典[M].北京：化学工业出版社,2000,第一版,294.
[31]Iwanuma Y,Chen F, Egilmez N, et al. Antitumor immune response of human periperal blood lymphocytes coengrafted with tumor into severe combined immmunodeficient mice [J].Cancer Res,1997,57(14):2937-2942
[32]宋萍,王学美,谢爽,等.鲜壁虎冻干粉抑制H22肿瘤血管生成机理的实验研究[J].中国中西医结合杂志,2006,26(1)：58-62.
[33]彭方兴,严律南.肝癌动物模型的研究进展[J].中华实验外科杂志,17(5)：475-476.
[34]徐静,李旭.肝癌动物模型的建立[J].实用肝脏病杂志,2005,8(2)：116-118.
[35]杨继金,朱永法,左长京,等.大白鼠转移性肝癌模型的制作[J].中华放射学杂志,1993,27：122-123.
[36]Jimbo T, Akimoto T, Tohgo A.Systemic administration of a synthetic lipid A derivative, DT-5461a, reduces tumor blood flow through endogenous TNF production in hepatic cancer model of VX2 carcinoma in rabbits[J]. Anticancer Res.1996,16(1): 359-364.
[37]Kuwata Y, Hirota S, Sako M.Treatment of metastatic liver tumors by intermittent repetitive injection of an angiogenesis inhibitor using an implantable port system in a rabbit model[J]. Kobe J Med Sci.1997,43(2):83-98.
[38]Celinski SA,Fisher WE,Amaya F,et al.Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts[J].J Surg Res,2003,115:41-47.
[39]叶燕丽,周听熙,王莲桂.裸鼠的繁殖及在肿瘤学中的应用[J].实验动物科学与管理,2005,22：6-8.
[40]Yao X,Hu JF,Daniels M,et al.A novel orthotopic tumor model study growth factors and oncogenes in hepatocarcinogenesis[J].Clin cancer Res,2003,9:2719-2726.
[41]何生,薛华.原发性肝癌治疗现状与评价[J].肝胆外科杂志,2000,8(3)：162-164.
[42]吴孟超.中医药在治疗肝癌中的地位、作用和存在的问题[J].中西医结合学报,2003,1(3)：163.
[43]蒋莲秀,赵一.常用治疗肝癌中药及作用机制研究进展[J].广西中医学院学报,2005,8(2)：73-76.
[44]郑界勋.以毒攻毒中药治疗原发性肝癌的文献研究[J].承德医学院学报,2009,26(1)：47-50.
[45]肖竺,田雪飞.单味中药抗肝癌实验研究进展[J].中国中医药信息杂志,2008,15(1)：100-102.
[46]钟毅,周红,伍耀衡,等.刘伟胜教授运用全蝎、蜈蚣治疗恶性肿瘤经验[J].新中医,2001,33(7)：7.
[47]张娟.焦中华治恶性肿瘤蜈蚣配伍经验[J].山东中医杂志,1999,18(9)：419-420.
[48]LaVallie ER, DiBlasio EA, Kovacic S, et al. A thiore-doxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm[J]. Bioteohnology (NY),1993,11(2):187-193.
[49]邓芬,方红,王克勤.中药蜈蚣毒溶血活性试验[J].中药材,1997,20(1)：36.
[50]安胜利,莫一心,欧春泉.在SPSS10.0软件上进行概率单位分析[J].第一军医大学学报,2002,22(11)：1019-1021.
[51]熊国娟,刘敏.临床应用蜈蚣不宜去头[J].时珍国医国药,2001,12(11)：983.
[52]冉永禄,吴刚,王金焕,等.墨江蜈蚣与少棘蜈蚣的比较研究-药效与毒理[J].动物学研究,1996,17(1)：79-83.
[53]张智,闪增郁,向丽华,等.15味有毒中药小鼠半数致死量的实验研究[J].中国中医基础医学杂志,2005,11(6)：435-436.
[54]中华人民共和国国家药品监督管理局.化学药物长期毒性研究技术指导原则,2005.3.
[55]中华人民共和国国家药品监督管理局.中药、天然药物长期毒性研究技术指导原则,2005.3.
[56]陈文彬,主编.诊断学(第5版)[M].北京：人民卫生出版社,2001,403.
[57]刘峰.蜈蚣的临床应用及其毒性研究[J].广西中医药,1999,22(4)：52-53.
[58]王家鹏,郭刚,王冉.“以毒攻毒”法治疗恶性肿瘤的现代研究[J].中医药学刊,2003,21(12)：2075-2076.
[59]吴良村,成文武,郭勇,等.吴良村中西医治疗原发性肝癌经验[J].浙江中医学院学报,2000,4：57.
[60]王庆才,李道明.王庆才治疗肝癌经验[J].辽宁中医药杂志,2000,9：395-397.
[61]司春富,谢有良.应用化疗法治疗肝癌的研究进展[J].河南中医,1999,10(60)：35-38.
[621苑淑芳,张俊富.病毒性肝炎肝硬化中医分型与肝癌血清学指标的关系[J].天津中医杂志,1997,14(3)：102-104.
[63]张存义,钱心兰.扶正祛邪法治疗肝癌之体会[J].上海中医药杂志,2000,11：22-23.
[64]傅凤霞,张正芳,王琦.原发性肝癌手术后辨证治疗60例[J].南京中医药大学学报,1997,13(5)：314-315.
[65]中华人民共和国卫生部/中国国家标准化管理委员会.GB15193.5-2003.中华人民共和国国家标准-骨髓细胞微核试验.北京：中国标准出版社,2003-09-24.
[66]中华人民共和国卫生部/中国国家标准化管理委员会.GB15193.7-2003.中华人民共和国国家标准-小鼠精子畸形试验.北京：中国标准出版社,2003-09-24.
[67]中华人民共和国卫生部/中国国家标准化管理委员会.GB15193.4-2003.中华人民共和国国家标准-鼠伤寒沙门氏菌/哺乳动物微粒体酶试验.北京：中国标准出版社,2003-09-24.
[68]肖凯,李宏霞.遗传毒性试验方法应用现况与研究进展[J].现代预防医学,2004,31(4)：524-526.
[69]中华人民共和国国家质量监督检验检疫总局.GB15193.1-2003.中华人民共和国国家标准-食品安全性毒理学评价程序.北京：中国标准出版社,2005-01-01.
[70]Elisabeth L, Carine L, Veronique G, et al. Genetic Toxicity Assessment:Employing the Best Science for Human Safety Evaluation Part Ⅱ:Performances of the In Vitro Micronucleus Test Compared to the Mouse Lymphoma Assay and the In Vitro Chromosome Aberration Assay[J]. Toxicol Sci,2007,96:214-217.
[71]李寿祺,主编.卫生毒理学基础[M].人民卫生出版社,2004.
[72]范瑞泉,魏青,丘钦英,等.小鼠精子畸形试验改良法与传统法效果比较[J].华南预防医学,2004,30(2)：51-52.
[73]Ames BN,Mccann J, Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test[J].Mutat Res,1975,31 (6):347-364.
[74]楼宜嘉,主编.药物毒理学(第2版)[M].北京：人民卫生出版社,2008,206.
[75]王心如,主编.毒理学基础(第5版)[M].北京：人民卫生出版社,2007,28.
[76]关建红,翁维良.对中药“毒性”与毒性分级的思考[J].中国中药杂志,2008,33(4)：485-487.
[77]杨仓良,主编.毒药本草[M].北京：中国中医药出版社,1993,14.
[78]翁维良.临床中药不良反应的探讨[J].中药新药与临床药理,1996,7(2)：4.
[79]杜贵友,方文贤.有毒中药现代研究和合理应用[M].北京：人民卫生出版社,2003.
[80]袁伯俊,王治乔,主编.新药临床前安全性评价与实践[M].北京：军事医学出版社,1997.
[81]周程,胡思安,龚昭,等.胆囊癌对化疗药物敏感性的研究[J].中年现代外科学杂志,2005,2(20)：1830-1832.
[82]宋晓伟,康健,林滢.改良的考马斯亮兰G250染色法简便快速测定微量蛋白浓度[J].洛阳医专学报,1997,16(3)：150-152.
[83]杨李,唐瑛,左娟,等.硫代巴比妥酸法测定血清脂质过氧化物方法的改进[J].华南国防医学杂志,2004,18(1)：30-32.
[84]张凤翔.黄嘌呤氧化酶氧化酶法测定血清中超氧化物歧化酶活力的影响因素[J].云南医药,2001,22(6)：473-474.
[85]林志彬,金有豫.药理学实习教程[M].世界图书出版公司,1989：73-77.
[861李娟,张耀庭,曾伟,等.应用考马斯亮兰法测定总蛋白含量[J].中国生物制品学杂志,2000,13(2)：118-120.
[87]徐叔云,主编.药理实验方法学[M].北京：人民卫生出版社,2002：514-515.
[88]谢青,赵钢德.肝细胞损伤分子生物学机制[J].中华肝脏病杂志,2008,16(9)：211-213.
[89]刘丹卓,赵新广.肝损伤病因病理机制及中医药治疗研究近况[J].国医论坛2006,21(6)：53-55.
[90]李艳辉,肖恩华.实验性肝损伤模型的建立和评价[J].放射学实践,2006,21(10)：1075-1077.
[91]汤新慧,高静.实验性肝损伤的损伤机制[J].中西医结合肝病杂志,2002,12(1)：53-55.
[92]苏俊芳,林铭育,李常青.抗纤软肝方对刀豆蛋白A致小鼠免疫性肝损伤的保护作用[J].中国热带医学,2008.8(7)：1094-1095.
u D, Thiele GM, Beckenhauer JL, et al. Detection of circulating antibodies to malondialdehyde-acetaldehyde adducts in ethanol-fed rats[J].Gastroenterology,1998, 115(3):686-692.
[941Rigamonti C, Mottaran E, Reale E, et al. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C[J]. Hepatology,2003,38(1):42-49.
[95]Vidali M, Hietala J, Occhino G, et al.Immune responses against oxidative stress-derived antigens are associated with increased circulating tumor necrosis factor-alpha in heavy drinkers[J]. Free Radic Biol Med,2008,45(3):306-311.
[96]杨牧祥,张一听,王少贤,等.柔肝消癥饮对肝硬化大鼠血清和肝组织IL-p、IL-6和TNF-a的影响[J].中华中医药杂志,2007,22(10)：729-731.
[97]Reinhart K, Menges T, Gardlund B, et al.Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis:the RAMSES Study [J]. Crit Care Med,2001,29,765-769.
[98]Roberto PF, Lindholm B, Axelsson J, et al. Update on interleukin-6 and its role in chronic renal failure [J]. Nephrol Dial Transplant,2003,18:1042-1045.
[99]姚光弼.药物性肝病[J].中华消化杂志,1999,19(5)：339-342.
[100]Fukui H, Wang NP, Watanabe T, et al.Solubilization, characterization and partial purification of [3H]mepyramine-binding protein, a possible histamine H1 receptor, from rat liver membrane[J]. Jpn J Pharmacol,1988,46(2):127-139.
[101]臧林泉,王乃平.肝脏中的细胞色素P-450与组胺受体[J].中国药理学通报,1993：9(6)：414-417.
[102]Mizuguchi H,Liu YQ,Fukui H,et al. Soludilization and characterization of H1 receptor in rat liver[J]. Jan J Pharmacal,1989,52(Suppl):180.
[103]Wang NP,Zhang LQ,Huang RB,et al.Determination of age-related changes of cytochrome P450 sensitive to mepyramine in rat hepatic microsomes[J].Acta Pharmaceutica Sinica,1995,30(10):726-730.
[104]方红,邓芳.蜈蚣药材中毒性成分组织胺的含量测定[J].中草药,1997,28(8)：472-473.
[105]陈继康,王言斌,张莉.鱼类组织胺含量测定及鲐巴鱼去组织胺的实验监测报告[J].中国卫生检疫杂志,2003,13(1)：98.
[106]孙黎黎,薛丰松.鱼类组织胺含量测定方法的改进[J].预防医学论坛,2005,11(2)：196-198.
[107]韶衡,李萍.肥大细胞激活及组织胺水平测定[J].华西医科大学学报,2002,33(4)：586-588.
[108]金成洙,吴龙仁,朴红心,等.磷酸组织胺诱导的I型超敏反应对肝损伤作用的研究[J].中国免疫学杂志,2007,12(23)：1140-1141.
i MA,Nassar SH,EI-Bassiouni EA,et al. Histamine and histamine receptor antagonists in splanchnic compartments in schistosomal portal hypertension[J]. Clin Pharmacol Ther,1988,44:396-405.
TF. Free radical mechanisms in tissue injury[J]. Biochem J,1984,222:1.
[1]张崇洲,土克勤.两种药用蜈蚣的简介[J].动物学杂志,1995,30(4)：51-54.
[2]王克勤,方红,叶卯祥.蜈蚣药源调查及商品鉴定[J].中药材,1997,20(9)：450-451.
[3]王克勤,陈厚祥,方红,等.药用蜈蚣源流考[J].时珍国药研究,1997,8(5)：385-386.
[4]国家药典委员会,编.中华人民共和国药典[M].北京：化学工业出版社,2000,第一版,294.
[5]唐宁群,邹长英.对蜈蚣毒性与用量的疑义[J].中医药研究,1999,15(4)：59.
[6]熊国娟,刘敏.临床应用蜈蚣不宜去头[J].时珍国医国药,2001,12(11)：983.
[7]江苏新医学院.中药大辞典·下册[M].上海：上海科学技术出版社,1986,2474.
[8]王端玲,程久菊.对临床应用蜈蚣的建议[J].中国药学杂志,1999,34(6)：393.
[9]迟程,罗天浩.蜈蚣毒性与用量的探讨[J].中国中药杂志,1995,15(6)：90.
[10]宋建徽,孟祥琴,王永利,等.蜈蚣提取物中枢抑制作用及急性毒性[J].河北医学院学报,1995,16(2)：90.
[11]李小莉,陈红琳,甘民.不同品种蜈蚣的抗炎、镇痛作用[J].中国中药杂志,1996,21(8)：498.
[12]周宜强.攻毒、排毒、解毒在治疗恶性肿瘤中的运用[J].世界中医药,2007,2(4)：200-2003.
[13]李向东.蜈蚣浅析新论[J].实用医技杂志,1996,3(7)：506.
[14]毛小平,陈子君,毛晓建,等.蜈蚣的部分药理研究[J].云南中医学院学报,1999,22(3)：1-4.
[15]李厚伟,张妍,许超千,等.中药HB对喉癌Hep22细胞的抑制作用及其机制研究[J].哈尔滨医科大学学报,2001,35(4)：261-262.
[16]曲爱兵,赵维成,梁良,等.蜈蚣组织提取物抗肿瘤活性的初步研究[J].实用肿瘤学杂志,2003,17(1)：29-30.
[17]许鸣镝,柳雪枚.蜈蚣碱性蛋白SSmp-d的分离纯化及其部分理化性质的鉴定[J].生物化学杂志,1997,13(5)：586-591.
[18]王贤纯.蜈蚣的药用研究进展[J].动物学杂志,2002,37(3)：88-91.
[19]刘国清,田秉漳,皮执民,等.蜈蚣油性提取液对肝癌细胞增殖的影响[J].中国现代医学杂志,2002,12(4)：55-56.
[20]焦波,娄红祥,王东兴,等.蜈蚣提取液对小鼠精原细胞的作用[J].山东医科大学学报,1999,37(4)：358.
[21]李风云,陈浩然,张蓄兰,等.中药制剂抗肿瘤作用的实验研究[J].中医药学报,1999,27(5)：57.
[22]刘德贵,苗艳波,张铁光,等.简述有毒动物药的抗肿瘤作用临床研究[J].吉林中医药,1998,18(6)：61.
[23]曾红,张国刚,程巨龙.蜈蚣中抗癌活性成分的提取[J].湖南中医杂志,2004,20(5)：57-58.
[24]黄金昶.“以毒攻毒”“温阳”“破淤”“通利二便”四法治疗肿瘤之我见[J].中国临床医生,2005,33(10)：51-52.
[25]孙谊,于智敏.“以毒攻毒”探源[J].中国中医基础医学杂志,2008,14(8)：584-585.
[26]陈士奎.“以毒攻毒”与中西医结合研究[J].医学与哲学,1998,19,4：186-187.
[27]王家鹏,郭刚,王冉.“以毒攻毒”法治疗恶性肿瘤的现代研究[J].中医药学刊,2003,21(12)：2075-2076.
[28]迟程,牛祖智.蜈蚣验方治百病[J].中国民族民间医药杂志,1996,21：23-30.
[29]薛功友,黄建华.济生颗粒加减治疗30例中晚期肺癌的临床研究[J].中国中医基础医学杂志,1999,5(2)：38-39.
[30]黄金昶,贾立群.“以毒攻毒”方药治疗恶性肿瘤[J].中日友好医院学报,2000,14(2)：117-120.
[31]李远东,张连新.中药散剂治疗肿瘤疼痛[J].中国民间疗法,1996,(1)：9.
[32]吴刚.蜈蚣毒的化学组成和生物活性[J].生物化学杂志,1992,8(2)：144.
[33]方红,邓芳.蜈蚣药材中毒性成分组织胺的含量测定[J].中草药,1997,28(8)：472.
[34]邓芬,方红,王克勤.中药蜈蚣毒溶血活性试验[J].中药材,1997,20(1)：36.
[35]左传田,祝家兴.组胺及其受体与原发性肺癌[J].实用肿瘤杂志,2000,15(2)：143-145.
[36]Grimbaldeston MA, Green A, Darlington S, et al. Susceptibility to basal cell carcinoma is associated with high dermal mast cell prevalence in non-sun-exposed skin for an Australian populations [J].Photochem Photobio,2003,78(6):633-639.
[37]Wan NP, Zang LQ, Huang RB, et al.The assay of antinlstamlnergic sensitive cytochrome p450 in rats[J]药学学报,1995,30(10)：726-730.
[38]Burtin C, Noirot C, Paupe J,et al. Decreased blood histamine levels in patients with solid malignant tumours[J]. Br J Cancer,1983,47(3):367-372.
[39]Burtin C, Noirot C, Giroux C, et al.Decreased skin response to intradermal histamine in cancer patients[J]. Allergy Clin Immunol,1986,78(1 Pt 1):83-89.
[40]Johansson M, Henriksson R, Bergenheim AT, et al.Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis inmalignantglioma[J]. Br J Cancer,2000,83(6):826-832.
[41]Rizell M,Hellstrand K,Lindner P,et al.Monotherapy with histamine dihydrochloride suppresses in vivo growth of a rat sarcoma in liver and subcutis [J]. Anticancer Res, 2002,22(4):1943-1948.
[42]Ohuchi Y, Yanai K, Sakurai E, et al. Histamine-induced calcium mobilization in single cultured cells expressing histamine H1 receptors:a relationship between its sensitivity and the density of H1 receptors [J]. J Mol Med,1998,1(2):355-360.
[43]Hellstrand K,Hansson M,Hermodsson S.Adjuvant histamine in cancer immuno-therapy[J]. Seminars in Cancer Biology,2000,10(1):29-39.
[44]Adams WJ, Lawson JA, Morris DL. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth[J]. Gut 1994,35:1632-1636.
[45]Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cell-mediated resistance against tumor cells[J]. J Immunol,1990,145(12):4365-4370.
[46]Johansson S, Landstrom M, Hellstrand K, et al.The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation[J]. Br J Cancer.1998,77(8): 1213-1219.
[47]曹漫明,汪森明,张积仁,等.组胺/IL-2联合激活的骨髓对移植物中肿瘤细胞的净化[J].癌症,2001,20(12)：1434-1435.
[48]Johansson M, Henriksson R, Bergenheim AT, et al.Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma[J].Br J Cancer,2000,83(6):826-832.
[49]Johansson S, Landstrom M, Henriksson R. Alterations of tumour cells, stroma and apoptosis in rat prostatic adenocarcinoma following treatment with histamine, interleukin-2 and irradiation[J]. Anticancer Res,1999,19(3A):1961-1969.
[50]何邦平,陈杰,张欣荣,等.微量元素与人体健康关系研究的回顾与展望[J].生命科学仪器,2003,1(1)：41-44.
[51]段飞,李发荣,杨建雄.微量元素与中药[J].陕西师范大学学报(自然科学版),2004,32：184-186.
[52]徐兆森,邵俭.微量元素与中药[J].辽宁药物与临床,2000,3(4)：182-184.
[53]冉永禄,吴刚,叶文娟,等.墨江蜈蚣与少棘蜈蚣的比较研究一Ⅰ化学组成[J].动物学研究,1995,16(4)379-383.
[54]姚惠英,曾宪周,卢成荣,等.肿瘤病人头发中微量元素的PIXE分析[J].中华肿瘤杂志,1988,10(2)：92.
[55]王智兴,张沪生,叶衍庆,朱世盛.骨巨细胞瘤瘤组织11种元素分析[J].肿瘤,1994,14(3)：149.
[56]闵锐.微量元素与血液系统某些恶性疾病的关系[J].国外医学输血及血液学分册,1989,12(2)：65.
[57]田柱萍,何邦平,王小燕,等.中药材的药效与其所含微量元素关系的研究进展[J].微量元素与健康研究,2005,22(4)：54-56.
[58]王亚丽.微量元素与中药抗癌[J].甘肃中医,1998,11(5)：43-44.
[59]Negri A,Llewellyn L.Comparative analyses by HPLC and the sodium channel and saxiphilin3H-saxitoxin receptor assays for paralytic shellfishtoxins in crustaceans and molliusks from tropical North West Australia[J].Toxicon,1998,36(2):283-298.
[60]Llewellyn L,Doyle J.Microtitre plate assays for paralytic shellfish toxins using saxiphilin,gauging the effects of shellfish extractmatrices,salts and pH upon assay performance[J].Toxicon,2001,39(2-3):217-224.
[1]Parkin DM,Bray F, Ferlay J,et al. Global cancer statistics[J].Cancer Clin, 2005,55:74-108.
[2]吴孟超.肝癌外科治疗的近期进展[J].中国普外基础与临床杂志,2006,13(2)：125-128.
[3]李连弟,张思维,鲁凤珠,等.中国恶性肿瘤死亡谱及分类构成特征研究[J].中华肿瘤杂志,1997,19：323-328.
[4]龚新雷,秦叔逵.原发性肝癌的分子靶向治疗研究新进展[J].临床肿瘤学杂志,2008.13(1)：1-9.
[5]Bismuth H, Morino M, Sherlock D, et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolization[J].Am J Surg,1992,163(4):387-394.
[6]Livraghi T, Lazzaroni S, Meloni F,et al. Intralesional ethanol in the treatment of unresectable liver cancer [J].World J Surg,1995,19(6):801-806.
[7]Sitzmann JV. Conversion of unresectable to resectable liver cancer:an approach and follow-up study[J].World J Surg,1995,19(6):790-794.
[8]Farmer DG, Rosove MH, Shaked A, et a/.Current treatment modalities for hepatocellular carcinoma[J].Ann Surg,1994,219(3):236-247.
[9]Ono Y, Yoshimasu T, Ashikaga R,et al.Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma[J]. Am J Clin Oncol.2000,23(6):564-568.
[10]何生,薛华.原发性肝癌治疗现状与评价[J].肝胆外科杂志,2000,8(3)：162-164.
[11]Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma [J]. J Clin Oncol,2003,21(3):421.
[12]Feun L G, O'Brien C, Molina E, et al. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patient s wit h hepatocellular carcinoma-A phase Ⅱ trial [J]. J Cancer Res Clin Oncol,2003,129(1):17.
[13]Leung TW, Part YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma [J]. Clin Cancer Res,1999,5(7):1676.
[14]Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy [J].Cancer, 2002,94(2):421.
[15]中国抗癌协会肝癌专业委员会.原发性肝癌规范化诊治的专家共识[J].胃肠病学和肝病学杂志,2009,1(6)：483-492.
[16]王中堂,李宝生,闰婧,等.原发性肝癌三维适形放疗后放射性肝病的相关因素分析[J].中华放射肿瘤学杂志,2007,16：281-285.
[17]Li B, Yu J, Wang L, Li C, et al. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma[J]. Am J Clin Oncol,2003,26(4):e92-99.
[18]Liu MT, Li SH, Chu TC, et al. Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization[J]. Jpn J Clin Oncol,2004(9),34:532-539.
[19]Cheng JC, Chuang VP, Cheng SH, et al. Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys,2000,47(2):435-442.
[20]Liang SX, Zhu XD, Lu HJ, et al.Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma[J].Cancer,2005,103(10):2181-2188.
[21]Kim TH, Kim DY, Park JW, et al.Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable [J]. Am J Clin Oncol,2006,29(6): 568-575.
[22]陆东东,陆培新.原发性肝癌的药物治疗进展[J].新医学,2001,32(4)：235-237.
[23]史仲华,郭彦君,刘德忠,等.132例原发性肝癌灌注化疗及栓塞治疗疗效观察[J].中华肿瘤杂志,1999,21(3)：211.
[24]Lu CL, Wu JC, Chiang JH, et al. Hepatocellular carcinoma in the caudate lobe: early diagnosis and active treatment may result in long-term survival [J].J Gastroenterol Hepatol,1997,12(2):144-148.
[25]刘康达,陆继珍,谭文翔,等.肝癌的门静脉血供研究及栓塞治疗[J].中华医学杂志,1995,75(7)：403-405.
[26]茅国新,于志坚,张一心,等.经导管肝动脉和B超引导下经细针门静脉双重化疗栓塞治疗原发性肝癌[J].中华肿瘤杂志,2002,24(4)：391-393.
[27]Gaiani S,Celli N,Cecilioni L,et al.Review article:percutaneous treatment of hepatocellular carcinoma[J].Aliment Pharmacol Ther,2003,17(Suppl2):103-110.
[28]Livraghi T, Benedini V.Lazzaroni S, et al. Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma [J]. Cancer,1998,83(1):48-57.
[29]Arii S,Yamaoka Y,Futagawa S,et al.Result of surgical and nonsurgicai treatment for Small-sized hepatollular carcinoma:A retrospective and nationwide survey in Japan[J].Hepatology,2000,32(6):1224-1229.
[30]吴孟超,吴东.原发性肝癌的外科治疗进展[J].临床外科杂志,2005,13(1)：4-7.
[31]Khan KN, Yatsuhashi H, Yamasaki K, et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection[J] J Hepatol,2000,32:269-278.
[32]Livraghi T, Benedini V, Lazzaroni S, et al. Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma[J]. Cancer,1998,83(1):48-57.
[33]庄振武,高雨东,李麟荪.超声导引经皮肝内注射乙酸的初步实验研究[J].南京医科大学学报,1997,17：457.
[341李拾林,吕国荣,李新丰.肝内注射致坏死剂的实验研究[J].中华超声影像学杂志,2000,9(8)：511.
[35]Garcea G, Lloyd TD, Aylott C, et al. The emergent role of focal liver ablation techniques in the treatment of primary and secondary liver tumours[J].Eur J Cancer,2003(15),1-15.
[36]Tamai T, Seki T, Imamura M,et al. Percutaneous injection of a low-concentration alkaline solution targeting hepatocellular carcinoma[J].Oncol Rep,2000,7(4):719-723.
[37]刘利民,张韵华,许根英.氢氧化钠溶液肿瘤瘤内注射的实验研究[J].中国超声医学杂志,2000,16(5)：325.
[38]Honda N, Guo Q, Uchida H, et al.Percutaneous hot saline injection therapy for hepatic tumors:an alternative to percutaneous ethanol injection therapy. Radiology[J].1994,190(1):53-57.
[39]Veltri A, Martina C, Bonenti G, et al.Therapy of malignant hepatic tumors using percutaneous hot saline injections. Feasibility study and preliminary results[J]. Radiol Med.1995,90(4):463-469.
[40]Yoon HK, Song HY, Sung KB, et al.Percutaneous hot saline injection therapy: effectiveness in large hepatocellular carcinoma[J].J Vase Interv Radiol.1999,10(4): 477-482.
[41]Huang JF,Kuang M,Lu M. Percutaneous hyperthermal distilled water injection therapy (PHDT) for liver cancer[J]. Asian J Surg,1999(22):337.
[42]周方平,苏健坤,张铁山,等.超声引导肝内注射高温蒸馏水对肝坏死的实验研究[J].中国临床医学影像杂志.2003,14(2)：137-138.
[43]周方平,苏健坤,王迎春,等.超声引导经皮肝内注射高温蒸馏水致肝坏死的病理学改变[J].医学影像学杂志2003,13(6)：422-423.
[44]叶胜龙.原发性肝癌非手术治疗的评价[J].中华肝脏病杂志,2003,11(12)：709-711.
[45]Rossi S, Buscarini E, Garbagnati F, et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode[J]. Am J Roentgenol,1998,170:1015-1022.
[46]Solbiati L, Goldberg SN, Ierace T, et al. Hepatic metastases:percutaneous radiofrequency ablation with cooled-tip electrodes[J].Radiology,1997,205:367-373.
[47]Livraghi T. Goldberg SN.Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection[J]. Riadiology, 1999,210(3):655-661.
[48]Dong B,Liang P,Yu X,et al.Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma:results in 234patients[J].Am J Roentgenol,2003,180(6):1547-1555.
[49]Itamoto T, Katayama K, Fukuda S, et al. Percutaneous microwave coagulation therapy for primary or recurrent hepatocellular carcinoma:long-term results [J] Hepatogastroenterology,2001,48(41):1401-1405.
[50]吕明德,陈俊伟,谢晓燕,等.超声引导瘤内高温治疗肝癌细胞癌[J].中华外科杂志,2001,7：502-504.
[51]Seki S, Sakaguchi H, Kadoya H, et al. Laparoscopic microwave coagulation therapy for hepatocellular carcinoma [J].Endoscopy,2000,32(8):591-597.
[52]Giorgio A, Tarantion L, de Stefano G, et al. Interstitial laser photocoagulation under ultrasound guidance of liver tumors:results in 104 treated patients[J].Eur J Ultrasound,2000,11(3):181-188.
[53]梁萍,董宝玮,顾瑛,等Nd:YAG激光热凝固肝组织的实验研究及肝癌治疗应用[J].中华理疗杂志,1999,22：158-160.
[54]Pacella CM, Bizzarri G, Cecconi P, et al. Hepatocellular carcinoma:long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization [J].Radiology,2001,219(3):669-678.
[55]周信达,汤钊猷,余业勤,等.液氮局部冷冻治疗肝癌[J].实用肿瘤杂志,1995,10：140-141.
[56]张保宁,张叔人,曲平,等.围冷冻手术期施行免疫疗法的抗肿瘤作用[J].中华肿瘤杂志,1999,21：427-428.
[57]郭发金,杨杨,张永强.高强度聚焦超声治疗肝癌的近期疗效评价fJ].中国医学影像技术,2004,20(2)：279-281.
[58]罗荣城,韩焕兴.肿瘤生物治疗学[M].北京：人民卫生出版社,2006：304.
[59]Atarashi Y, Yasumura S,Nambu S,et al. A novel human tumor necrosis factor alfa mutein, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma:implication for immunotherapy of human hepatocellular carcinoma[J]. Hepatology,1998,28(1):57-67.
[60]Kubo S,Nishiguchi S,Hirohashi K,et al. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy[J].Br J Surg,2002,89(4):418-422.
[61]Lin SM, Lin CJ, Hsu CW, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors [J].Cancer,2004,100(2):376-382.
[62]Penichet ML,Morrison SL. Antibody-cytokine fusion proteins for the therapy of cancer[J] J Immunol Methods,2001,248(1-2):91-101.
[63]Yajun G,Mengchao W, Han C, et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells[J].Science,1994,263 (5146):518-520.
[64]Chung W L.Natural riller cell activity in patients with HCC relative to early development and tumor invasion[J].Cancer,1996,71(4):926-928.
[65]Iwashita Y, Tahara K, Goto S, et al.A phase Ⅰ study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer[J]. Cancer Immunol Immunother.2003,52(3):155-161.
[66]Palmer DH, Midgley RS, Mirza N, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology[J].2009,49(1):124-132.
[67]Buterfield LH. Immunotherapeutic strategies for hepatocellular carcinoma[J]. Gastroenterology,2004, (5 Suppl 1):S232-241.
[68]Schulze T, Kemmner W, Weitz J, et al. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases:results of a prospective randomized trial[J]. Cancer Immunol Immunother,2009,58(1):61-69.
[69]Lan YH, Li YG, Liang ZW,et al. A DNA vaccine against chimeric AFP enhanced by HSP70 suppresses growth of hepatocellular carcinoma [J]. Cancer Immunol Immunother.2007,56(7):1009-1016.
[70]杨冬华.肝癌的免疫治疗现状及前景[J].中华肝脏病杂志,2003,11(12)：757.
[711钟珍,苏科,周汉新,等.人转铁蛋白修饰载阿霉素海藻酸钠纳米粒的制备与评价[J].中国组织工程研究与临床康复,2010,14(21)：3861-3864.
[72]楼敏.双特异性抗体在肿瘤免疫治疗中的作用[J].国外医学肿瘤学分册,1997,24：212-214.
[73]Takayama T, Sekine T,Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma:a randomised trial [J]. Lancet,2000,356 (9232):802-807.
[74]O'Beirne JP, Harrison PM. The role of the immune system in the control of hepatocellular carcinoma[J].Eur J Gast roenterol Hepatol,2004,16(12):1257-1260.
[751陈孝平,张万广.肝细胞性肝癌实验研究的热点与展望[J].中华实验外科杂志,2006,23(3)：264-265.
[76]Wang XW,Yuan JH,Ghang BG, et al. Antihepatoma effect of alpha-fetoprotein antisense phosphorothioate oligodeoxyribonucleotides in vitro and in mice[J]. World J Gastmenterol,2001,7(3):345-351.
[77]Qian C,Drozdzik M,Caselmann WH,et al. The potential of gene therapy in the treatment of hepatocellular carcinoma[J].J Hepatol,2000,32(2):344-351.
[78]Schmitz V,Qian C,Ruiz J,et al. Gene therapy for liver diseases:recent strategies for treatment of viral hepatitis and liver malignancies [J].Gut,2002,50(1):130-135.
[79]Drozdzik M,Qian C, Xie X, et al. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma [J].J Hepatol,2000,32(2):279-286.
[80]Huber BE.Richards CA.Krenitsky TA, et al. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma:an innovative approach for cancer therapy [J]. Proc Natl Acad Sci,1991,88(18):8039-8043.
[81]Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine:a negative selection system[J].Proc Natl Acad Sci,1992,89(l):33-37.
[82]Barajas M,Mazzolini G,Genove G,et al. Gene therapy of orthotropic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12 [J]. Hepatoiogy,2001, 33(1):52-61.
[83]Harada N,Shimada M,Okano S,et al. IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice[J].J Immunol,2004,173(11):6635-6644.
[84]Kahlenberg MS, Stoler DL, Basik M, et al. p53 Tumor Suppressor Gene Status and the Degree of Genomic Instability in Sporadic Colorectal Cancers[J]. Journal of the National Cancer Institute,1996,88(22):1665-1669.
[85]Qian C,Drozdzik M,Caselmann WH,et al. The potential of gene therapy in the treatment of hepatocellular carcinoma[J].J Hepatol,2000,32(2):344-351.
[86]Marx J. Angiogenesis:A boost for tumor starvation[J].Science,2003,301(5632): 452-454.
[87]叶义标,陈涛.肝癌血管生成与抗血管生成治疗的研究进展[J].中国普外基础与临床杂志,2009,16(10)：861-865.
[88]McNeish IA, Bell SJ, Lemoine NR.Gene Therapy Progress and Prospects:cancer gene therapy using tumour suppressor genes.Gene Ther,2004,11(6):497-503.
[89]Yoshimura I, Mizuguchi Y, Miyajima A, et al.Suppression of lung metastasis of renal cell carcinoma by the intramuscular gene transfer of a soluble form of vascular endothelial growth factor receptor I [J]. J Urol,2004,171(6):2467-2470.
[90]Hotz HG, Hines OJ,Masood R,et al. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer [J].Surgery, 2005,137(2):192-199.
[91]陈慧玲,白海.肿瘤多药耐药的研究进展[J].临床肿瘤学杂志,2008,13(5)：475- 477.
[92]胡礼仪,张有顺,周新,等.MDR短发夹RNA表达质粒的构建及其功能的初步研究[J].肿瘤,2004,24(6)：542-525.
[93]Wu H, Hait WN, Yang JM.Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells [J]. Cancer Res.2003,63(7):1515-1519.
[94]黄金昶.“以毒攻毒”“温阳”“破淤”“通利二便”四法治疗肿瘤之我见[J].中国临床医生,2005,33(10)：51-52.
[95]孙谊,于智敏.“以毒攻毒”探源[J].中国中医基础医学杂志,2008,14(8)：584-585.
[96]陈士奎.“以毒攻毒’”与中西医结合研究[J].医学与哲学,1998,19,4：186-187.
[97]王家鹏,郭刚,王冉.“以毒攻毒”法治疗恶性肿瘤的现代研究[J].中医药学刊,2003,21(12)：2075-2076.
[98]郑界勋.以毒攻毒中药治疗原发性肝癌的文献研究[J].承德医学院学报,2009,26(1)：47-50.